<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Acute tocolysis for uterine tachysystole or suspected fetal distress - Leathersich, SJ - 2018 | Cochrane Library</title> <meta content="Acute tocolysis for uterine tachysystole or suspected fetal distress - Leathersich, SJ - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009770.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Acute tocolysis for uterine tachysystole or suspected fetal distress - Leathersich, SJ - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009770.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009770.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Acute tocolysis for uterine tachysystole or suspected fetal distress" name="citation_title"/> <meta content="Sebastian J Leathersich" name="citation_author"/> <meta content="King Edward Memorial Hospital for Women" name="citation_author_institution"/> <meta content="sebastian.leathersich@health.wa.gov.au" name="citation_author_email"/> <meta content="Joshua P Vogel" name="citation_author"/> <meta content="World Health Organization" name="citation_author_institution"/> <meta content="Thach Son Tran" name="citation_author"/> <meta content="Garvan Institute of Medical Research" name="citation_author_institution"/> <meta content="G Justus Hofmeyr" name="citation_author"/> <meta content="Walter Sisulu University, University of the Witwatersrand, Eastern Cape Department of Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009770.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/07/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009770.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009770.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009770.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐2 Receptor Agonists [therapeutic use]; Cesarean Section [statistics &amp; numerical data]; Fenoterol [therapeutic use]; Fetal Distress [*drug therapy]; Hexoprenaline [therapeutic use]; Nitroglycerin [therapeutic use]; Perinatal Death; Randomized Controlled Trials as Topic; Terbutaline [therapeutic use]; Tocolysis [*methods]; Tocolytic Agents [*therapeutic use]; Uterine Contraction [*drug effects]; Vasotocin [analogs &amp; derivatives, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009770.pub2&amp;doi=10.1002/14651858.CD009770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009770\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009770\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009770.pub2",title:"Acute tocolysis for uterine tachysystole or suspected fetal distress",firstPublishedDate:"Jul 4, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009770.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009770.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009770.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009770.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009770.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009770.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009770.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009770.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009770.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009770.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13463 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009770.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0156"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-sec-0150"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/appendices#CD009770-sec-0161"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/table_n/CD009770StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/table_n/CD009770StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Acute tocolysis for uterine tachysystole or suspected fetal distress</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#CD009770-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sebastian J Leathersich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#CD009770-cr-0003">Joshua P Vogel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#CD009770-cr-0004">Thach Son Tran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information#CD009770-cr-0005">G Justus Hofmeyr</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information/en#CD009770-sec-0166">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 July 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009770.pub2">https://doi.org/10.1002/14651858.CD009770.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009770-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009770-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009770-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009770-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009770-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009770-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009770-abs-0001" lang="en"> <section id="CD009770-sec-0001"> <h3 class="title" id="CD009770-sec-0001">Background</h3> <p>Uterine tachysystole (more than 5 contractions per 10 minutes in 2 consecutive intervals) is common during labour, particularly with use of labour‐stimulating agents. Tachysystole may reduce fetal oxygenation by interrupting maternal blood flow to the placenta during contractions. Reducing uterine contractions may improve placental blood flow, improving fetal oxygenation. This review aimed to evaluate the use of tocolytics to reduce or stop uterine contractions for improvement of the condition of the fetus in utero. This new review supersedes an earlier Cochrane Review on the same topic. </p> </section> <section id="CD009770-sec-0002"> <h3 class="title" id="CD009770-sec-0002">Objectives</h3> <p>To assess the effects of the use of acute tocolysis during labour for uterine tachysystole or suspected fetal distress, or both, on fetal, maternal and neonatal outcomes. </p> </section> <section id="CD009770-sec-0003"> <h3 class="title" id="CD009770-sec-0003">Search methods</h3> <p>We searched Cochrane Pregnancy and Childbirth's Trials Register, <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (2 February 2018), and reference lists of retrieved studies. </p> </section> <section id="CD009770-sec-0004"> <h3 class="title" id="CD009770-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) evaluating acute tocolysis for uterine tachysystole, intrapartum fetal distress, or both. </p> </section> <section id="CD009770-sec-0005"> <h3 class="title" id="CD009770-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by Cochrane.</p> </section> <section id="CD009770-sec-0006"> <h3 class="title" id="CD009770-sec-0006">Main results</h3> <p>We included eight studies (734 women), conducted in hospital settings, predominantly in high‐income countries (USA, Austria, Uruguay). Two trials were conducted in upper and lower middle‐income countries (South Africa, Sri Lanka). The hospital facilities all had the capacity to perform caesarean section. Overall, the studies had a low risk of bias, except for methods to maintain blinding. All of the trials used a selective beta<sub>2</sub> (ß<sub>2</sub>)‐adrenergic agonist in one arm, however the drug used varied, as did the comparator. Limited information was available on maternal outcomes. </p> <p><b>Selective ß<sub>2</sub>‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</b> </p> <p>There were two stillbirths, both in the no tocolytic control group (risk ratio (RR) 0.23, 95% confidence interval (CI) 0.01 to 4.55; 2 studies, 57 women; low‐quality evidence). One had gross hydrocephalus and the second occurred with vaginal delivery after waiting 55 minutes for caesarean section. The decision for caesarean section delivery was an inclusion criterion in both studies so we could not assess this as an outcome under this comparison. Abnormal fetal heart trace is probably lower with tocolytic treatment (RR 0.28, 95% CI 0.08 to 0.95; 2 studies, 43 women; moderate‐quality evidence). The effects on the number of babies with Apgar score below seven were uncertain (low‐quality evidence). </p> <p><b>Intravenous (IV) atosiban versus IV hexoprenaline (1 study, 26 women)</b> </p> <p>One infant in the hexoprenaline group required &gt; 24 hours in the neonatal intensive care unit (NICU) following a forceps delivery (RR 0.33, 95% CI 0.01 to 7.50; low‐quality evidence). There were no fetal or neonatal mortalities and no Apgar scores below seven. There was one caesarean delivery in the IV hexoprenaline group (RR 0.33, 95% CI 0.01 to 7.50; low‐quality evidence), and one case of abnormal fetal heart score in the atosiban group (RR 3.00, 95% CI 0.13 to 67.51; very low‐quality evidence). </p> <p><b>IV fenoterol bromhydrate versus emergency delivery (1 study, 390 women)</b> </p> <p>No data were reported for perinatal death, severe morbidity or fetal or neonatal mortality. IV fenoterol probably increases the risk of caesarean delivery (RR 1.12, 95% CI 1.04 to 1.22; moderate‐quality evidence). Fenoterol may have little or no effect on the risk of Apgar scores below seven (RR 1.28, 95% CI 0.35 to 4.68; low‐quality evidence). </p> <p><b>IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery (1 study, 37 women)</b> </p> <p>No data were reported for perinatal death or severe morbidity. There were two fetal deaths in the no tocolytic control group (RR 0.23, 95% CI 0.01 to 4.55; low‐quality evidence). The rate of caesarean delivery was not reported. There were two babies with Apgar scores below seven in the control group and none in the hexoprenaline group (RR 0.24, 95% CI 0.01 to 4.57; 35 women; low‐quality evidence). </p> <p><b>Subcutaneous terbutaline versus IV magnesium sulphate (1 study, 46 women)</b> </p> <p>No data were reported for perinatal death, severe morbidity or fetal or neonatal mortality. The decision for caesarean section was an inclusion criterion, so we could not assess this. The effects on abnormal fetal heart trace are uncertain (very low‐quality evidence). </p> <p><b>Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent (1 study, 28 women)</b> </p> <p>No data were reported for perinatal death, severe morbidity or fetal or neonatal mortality. There may be little or no difference in the rates of caesarean delivery in the subcutaneous terbutaline (8/15) and control groups (4/13) (RR 1.73, 95% CI 0.68 to 4.45; low‐quality evidence). There were no cases of Apgar scores below seven or abnormal fetal heart trace. </p> <p><b>Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery (1 study, 20 women)</b> </p> <p>No data were reported for perinatal death or severe morbidity. There were no fetal or neonatal mortalities. The decision for caesarean section was an inclusion criterion, so we could not assess this. There were two babies with Apgar scores below seven in the control group and none in the terbutaline group (RR 0.17, 95% CI 0.01 to 3.08; low‐quality evidence). </p> <p><b>IV terbutaline versus IV nitroglycerin (1 study, 110 women)</b> </p> <p>No data were reported for perinatal death or severe morbidity or fetal or neonatal mortality. There may be little or no difference in the rates of caesarean delivery between the IV terbutaline (30/57) and control groups (29/53) (RR 0.96, 95% CI 0.68 to 1.36; low‐quality evidence). There were no cases of Apgar scores below seven. </p> </section> <section id="CD009770-sec-0007"> <h3 class="title" id="CD009770-sec-0007">Authors' conclusions</h3> <p>There is insufficient evidence to determine the effects of tocolytics for uterine tachysystole or suspected fetal distress during labour. The clinical significance for some of the improvements in measures of fetal well‐being with tocolytics is unclear. The sample sizes were too small to detect effects on neonatal morbidity, mortality or serious adverse effects. The majority of studies are from high‐income countries in facilities with access to caesarean section, which may limit the generalisability of the results to lower‐resource settings, or settings where caesarean section is not available. </p> <p>Further well‐designed and adequately powered RCTs are required to evaluate clinically relevant indicators of maternal and neonatal morbidity and mortality. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009770-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009770-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009770-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009770-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009770-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009770-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009770-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009770-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009770-abs-0004" lang="en"> <h3>Medications for reducing contractions during labour for excessively strong/frequent contractions or where the unborn baby is thought to be distressed </h3> <p><b>What is the issue?</b> </p> <p>Excessively strong or frequent contractions can occur in any labour, though are more common when women have been given medications to start off or increase contractions. In some cases, excessive contractions can be a sign of complications such as placental abruption or obstructed labour. Excessive contractions may reduce the amount of oxygen reaching the unborn baby. </p> <p>'Tocolysis' is when women are given medication to reduce the strength or frequency of contractions, or both. Tocolysis may improve blood flow and therefore improve the baby's well‐being. This review aimed to evaluate the benefits and harms of tocolysis when the uterus (womb) is contracting too quickly (more than 5 contractions in 2 consecutive 10‐minute periods) or when the baby is showing signs of distress during labour, as detected by monitoring its heart rate. </p> <p>This new Cochrane Review supersedes an earlier Cochrane Review with the same name.</p> <p><b>Why is this important?</b> </p> <p>Babies who are deprived of oxygen during labour can develop serious problems, including cerebral palsy, organ damage or death. When fetal monitoring suggests fetal distress, measures can be taken to improve the baby's oxygen levels. This can include the use of tocolytic medications. This may be particularly important in low‐resource environments, where an emergency delivery or caesarean section may not be immediately available. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence in February 2018 and found eight randomised controlled trials (involving 734 women) who had excessive uterine contractions, signs of fetal distress, or both during labour. The trials tested different comparison groups, which means that our analyses were based on data from single studies involving small numbers of women. Women were randomised to receiving a β<sub>2</sub>‐adrenergic tocolytic drug or an alternative approach (including no tocolytic while awaiting caesarean section, stopping medications that increase contraction strength, or using a different tocolytic such as atosiban, magnesium sulphate or nitroglycerin). </p> <p>We combined data from two small trials (57 women), comparing a β<sub>2</sub>‐adrenergic tocolytic drug with no tocolytic drug. Two babies died in their mother's womb, both occurring in the group of women who did not receive a tocolytic ‐ one had gross hydrocephalus (too much fluid in and around the brain) and the other occurred whilst the mother was waiting to have a caesarean section. The number of babies with an abnormal fetal heart rate is probably lower in the group of women who were given a tocolytic, but the effects on other measures of infant well‐being were uncertain. </p> <p>Very few serious side effects were found, but the studies were too small to assess uncommon adverse effects. </p> <p>It is not possible to draw clear conclusions about the benefits and harms and the quality of the evidence was very low to moderate. </p> <p><b>What does this mean?</b> </p> <p>There is not enough evidence from randomised controlled trials to determine the effects of tocolysis for women with fetal distress or excessive uterine contractions, nor to identify whether one type of tocolytic drug is safer or more effective than another. </p> <p>The clinical significance for some of improvements in measures of fetal well‐being with tocolytics is unclear. Generally, sample sizes were too small to detect effects on maternal or infant well‐being or serious adverse effects. The majority of studies were from high‐income countries in healthcare facilities with access to caesarean section, which may limit the applicability of these results to lower‐resource settings, or settings where caesarean section is not available. </p> <p>Further high‐quality studies, involving large numbers of women, are needed. Such studies could focus on measuring clinically relevant outcomes for the mother and her baby such as death of the mother, her baby, and other measures of well‐being and safety. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009770-sec-0156" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009770-sec-0156"></div> <h3 class="title" id="CD009770-sec-0157">Implications for practice</h3> <section id="CD009770-sec-0157"> <p>There is insufficient evidence to determine the effects of tocolytics for uterine tachysystole or suspected fetal distress during labour. The clinical significance for some of the improvements in measures of fetal well‐being with tocolytics is unclear. The sample sizes were too small to detect effects on neonatal morbidity, mortality or serious adverse effects. The majority of studies are from high‐income countries in facilities with access to caesarean section, which may limit the generalisability of the results to lower‐resource settings, or settings where caesarean section is not available. </p> </section> <h3 class="title" id="CD009770-sec-0158">Implications for research</h3> <section id="CD009770-sec-0158"> <p>There is a need for well‐designed and adequately powered randomised controlled trials examining the effects of tocolysis with different agents on fetus, neonate and mother. </p> <p>It would be helpful if future studies collected data on clinically important maternal and neonatal outcomes to inform assessment of the benefits and harms of interventions, and were adequately powered to detect serious adverse events. In particular, data relating to neonatal morbidity and mortality and condition at birth are required to assess the clinical implications of tocolytic treatment. In the absence of clear evidence to support the use of tocolytics in cases of uterine tachysystole or fetal distress, trials could be placebo‐controlled where possible. It would be useful to consider separately addressing two distinct management approaches: using tocolysis after the decision for emergency delivery has been made as an interim measure, versus using tocolysis as a treatment for tachysystole or fetal distress, without having committed to a specific mode of delivery. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009770-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009770-sec-0029"></div> <div class="table" id="CD009770-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Selective ß<sub>2</sub>‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with fetal distress for whom the decision had been made to delivery by emergency caesarean section<br/> <b>Setting:</b> hospitals with the capacity for caesarean section in South Africa or the United States<br/> <b>Intervention:</b> ß<sub>2</sub>‐adrenergic receptor agonist whilst awaiting emergency delivery<br/> <b>Comparison:</b> no tocolytic whilst awaiting emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no tocolytic agent whilst awaiting emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ß<sub>2</sub>‐ adrenergic receptor agonist whilst awaiting emergency delivery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/> (0.01 to 4.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (1 to 314) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery was an inclusion criteria for both trials</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/> (0.02 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (3 to 224) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low umbilical artery pH (less than 7.0 or as defined by trial authors)</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abnormal FHR as defined by trial authors (FHR tracing not improved)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.28<br/> (0.08 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>947 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/> (133 to 521) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Wide confidence interval crossing the line of no effect (‐1).<br/> <sup>2</sup>Small sample size (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for IV atosiban versus IV hexoprenaline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV atosiban versus IV hexoprenaline for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with severe intrapartum fetal bradycardia<br/> <b>Setting:</b> Austrian hospital with capacity for caesarean section<br/> <b>Intervention:</b> IV atosiban (6.75 mg)<br/> <b>Comparison:</b> IV hexoprenaline (5 µg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV hexoprenaline</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV atosiban</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 7.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 577) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>26</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 (0 to 0)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 7.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical artery pH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean umbilical artery pH was 7.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in umbilical artery pH in the intervention group was 0 (0.05 fewer to 0.05 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Abnormal FHR tracing</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 3.00<br/> (0.13 to 67.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>26<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Small sample size (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect (‐1).<br/> <sup>3</sup>Few/no events (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for IV fenoterol bromhydrate versus emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV fenoterol versus emergency delivery for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole<br/> <b>Setting:</b> hospital in Uruguay with capacity for caesarean section<br/> <b>Intervention:</b> IV fenoterol bromhydrate (0.1 mg/minute, titrated according to response)<br/> <b>Comparison:</b> emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV fenoterol bromhydrate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (1.04 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>807 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>904 per 1000<br/> (839 to 985) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/> (0.35 to 4.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (7 to 95) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/> (0.44 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/> (94 to 224) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal FHR tracing</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Participants, clinicians and assessors were not blinded. There were risks identified for reporting bias (‐1).<br/> <sup>2</sup>Confidence interval crossing the line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings for IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring<br/> <b>Setting:</b> hospital in South Africa with capacity for caesarean section<br/> <b>Intervention:</b> IV hexoprenaline (10 µg) whilst awaiting emergency delivery<br/> <b>Comparison:</b> no tocolytic whilst awaiting emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no tocolytic whilst awaiting emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV hexoprenaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/> (0.01 to 4.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (1 to 455) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/> (0.01 to 4.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 481) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/> (0.30 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>588 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>376 per 1000<br/> (176 to 794) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>FHR tracing not improved</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.43<br/> (0.21 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000<br/> (189 to 792) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Small sample size (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline versus IV magnesium sulphate</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subcutaneous terbutaline versus IV magnesium sulphate for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with intrapartum fetal distress for whom the decision had been made to deliver by caesarean section<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> subcutaneous terbutaline (250 µg) followed by caesarean section within 15 minutes<br/> <b>Comparison:</b> IV magnesium sulphate (4 g) followed by caesarean section within 15 minutes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV magnesium sulphate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous terbutaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.2</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.29<br/> (0.07 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>46<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>304 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (21 to 374) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resolution of fetal distress on FHR tracing</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.31<br/> (0.97 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>46<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>696 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>911 per 1000<br/> (675 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Participants, clinicians and assessors unblinded (‐1).<br/> <sup>2</sup>Small sample size (‐1).<br/> <sup>3</sup>Confidence interval crossing the line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent for the management of uterine hyperstimulation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women who developed uterine hyperstimulation in labour with oxytocin augmentation, but without signs of fetal distress<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> subcutaneous terbutaline (250 µg, up to 3 doses 15 minutes apart) with continuation of the oxytocin infusion<br/> <b>Comparison:</b> cessation of the oxytocin infusion without administration of a tocolytic </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with cessation of oxytocic infusion without tocolytic</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous terbutaline with continuation of oxytocic</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.73<br/> (0.68 to 4.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532 per 1000<br/> (209 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal FHR tracing</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No blinding of participants, clinicians or assessors (‐1).<br/> <sup>2</sup>Confidence interval crossing the line of no effect (‐1).<br/> <sup>3</sup>No events in either group (‐1).<br/> <sup>4</sup>Small sample size (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in labour with signs of fetal distress and a fetal scalp pH &lt; 7.25, for whom the decision had been made for emergency delivery<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> subcutaneous terbutaline (250 µg) whilst awaiting emergency delivery<br/> <b>Comparison:</b> no tocolytic whilst awaiting emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no tocolytic whilst awaiting emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous terbutaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.17<br/> (0.01 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (2 to 684) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical artery pH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean umbilical artery pH in the intervention group was 0.08 more (0.06 more to 0.1 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abnormal FHR tracing</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.33 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>570 per 1000<br/> (330 to 980) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No improvement in FHR</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.13<br/> (0.03 to 0.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000<br/> (30 to 590) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval crossing the line of no effect (‐1).<br/> <sup>2</sup>Small sample size (‐1).<br/> <sup>3</sup>No events in either group (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009770-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings for IV terbutaline versus IV nitroglycerin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV terbutaline versus IV nitroglycerin for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with non‐reassuring FHR tracing during labour or induction of labour<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> IV terbutaline (250 µg)<br/> <b>Comparison:</b> IV nitroglycerin (400 µg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV nitroglycerin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV terbutaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.68 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>547 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000<br/> (372 to 744) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.87<br/> (0.24 to 98.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Successful intrauterine fetal resuscitation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12</p> <p>(0.87 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>718 per 1000</p> <p>(559 to 932)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval crossing the line of no effect (‐1).<br/> <sup>2</sup>No events in either group (‐1).<br/> <sup>3</sup>Small sample size (‐1).<br/> <sup>4</sup>Extremely wide confidence interval (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009770-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009770-sec-0030"></div> <p>Excessive uterine activity is termed uterine tachysystole or hyperstimulation, though the latter term should be abandoned because of potential confusion (<a href="./references#CD009770-bbs2-0029" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstetrics &amp; Gynecology2009;114(1):192‐202. ">ACOG 2009</a>). Uterine tachysystole, defined as more than five uterine contractions per 10 minutes in at least two consecutive intervals (<a href="./references#CD009770-bbs2-0029" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstetrics &amp; Gynecology2009;114(1):192‐202. ">ACOG 2009</a>), is not uncommon during labour (<a href="./references#CD009770-bbs2-0035" title="CraneJM , YoungDC , ButtKD , BennettKA , HutchensD . Excessive uterine activity accompanying induced labor. Obstetrics &amp; Gynecology2001;97(6):926‐31. ">Crane 2001</a>). It was documented in at least one‐fifth of women with spontaneous onset of labour who had not received any labour augmentation, and in 48.6% of women whose labour had been induced by prostaglandin (<a href="./references#CD009770-bbs2-0035" title="CraneJM , YoungDC , ButtKD , BennettKA , HutchensD . Excessive uterine activity accompanying induced labor. Obstetrics &amp; Gynecology2001;97(6):926‐31. ">Crane 2001</a>). Similarly, non‐reassuring fetal heart rate (FHR) patterns are commonly reported during active labour (<a href="./references#CD009770-bbs2-0033" title="BloomSL , SpongCY , ThomE , VarnerMW , RouseDJ , WeiningerS , et al. Fetal pulse oximetry and cesarean delivery. New England Journal of Medicine2006;355(21):2195‐202. ">Bloom 2006</a>; <a href="./references#CD009770-bbs2-0039" title="GariteTJ , DildyGA , McNamaraH , NageotteMP , BoehmFH , DellingerEH , et al. A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns. American Journal of Obstetrics and Gynecology2000;183(5):1049‐58. ">Garite 2000</a>). Although uterine tachysystole is more commonly noted after the use of labour‐stimulating agents, it may also be a clinical sign of serious pregnancy complications, such as placental abruption or obstructed labour. </p> <section id="CD009770-sec-0031"> <h3 class="title" id="CD009770-sec-0031">Description of the condition</h3> <p>Uterine contraction compresses maternal spiral arteries and increases the intraplacental pressure, profoundly reducing the placental blood flow when the intraplacental pressure exceeds the pressure of maternal perfusion to the placenta (<a href="./references#CD009770-bbs2-0034" title="BrarHS , PlattLD , DeVoreGR , HorensteinJ , MedearisAL . Qualitative assessment of maternal uterine and fetal umbilical artery blood flow and resistance in laboring patients by Doppler velocimetry. American Journal of Obstetrics and Gynecology1988;158(4):952‐6. ">Brar 1988</a>; <a href="./references#CD009770-bbs2-0038" title="FleischerA , AnyaegbunamAA , SchulmanH , FarmakidesG , RandolphG . Uterine and umbilical artery velocimetry during normal labor. American Journal of Obstetrics and Gynecology1987;157(1):40‐3. ">Fleischer 1987</a>; <a href="./references#CD009770-bbs2-0046" title="McNamaraH , JohnsonN . The effect of uterine contractions on fetal oxygen saturation. BJOG: an international journal of obstetrics and gynaecology1995;102(8):644‐7. ">McNamara 1995</a>). It was reported that a contraction at 30 mmHg or more was able to diminish or even interrupt maternal blood flow to the placenta and potentially reduces fetal oxygenation status (<a href="./references#CD009770-bbs2-0034" title="BrarHS , PlattLD , DeVoreGR , HorensteinJ , MedearisAL . Qualitative assessment of maternal uterine and fetal umbilical artery blood flow and resistance in laboring patients by Doppler velocimetry. American Journal of Obstetrics and Gynecology1988;158(4):952‐6. ">Brar 1988</a>; <a href="./references#CD009770-bbs2-0038" title="FleischerA , AnyaegbunamAA , SchulmanH , FarmakidesG , RandolphG . Uterine and umbilical artery velocimetry during normal labor. American Journal of Obstetrics and Gynecology1987;157(1):40‐3. ">Fleischer 1987</a>). In one study, fetal oxygenation saturation, quantitatively measured by an intrauterine sensor, reached its nadir 92 seconds after the peak of a contraction, and took another 90 seconds to obtain complete recovery (<a href="./references#CD009770-bbs2-0046" title="McNamaraH , JohnsonN . The effect of uterine contractions on fetal oxygen saturation. BJOG: an international journal of obstetrics and gynaecology1995;102(8):644‐7. ">McNamara 1995</a>). Normal labour with sufficient physiological relaxation time allows the oxygenation level of an uncompromised baby to be restored between contractions. </p> <p>The compensatory fetoplacental mechanism may no longer be effective in the presence of uterine tachysystole, which is usually associated with strong contractions of 80 mmHg or more (<a href="./references#CD009770-bbs2-0031" title="BakkerPC , KurverPH , KuikDJ , VanGeijnHP . Elevated uterine activity increases the risk of fetal acidosis at birth. American Journal of Obstetrics and Gynecology2007;196(4):313. ">Bakker 2007</a>), and significantly shortened relaxation time. Strong contractions contribute to further compression of maternal spiral arteries, while a shortened relaxation time presumably does not allow the blood supply to the placenta to return to baseline levels before the next contraction (<a href="./references#CD009770-bbs2-0047" title="PeeblesDM , SpencerJA , EdwardsAD , WyattJS , ReynoldsEO , CopeM , et al. Relation between frequency of uterine contractions and human fetal cerebral oxygen saturation studied during labour by near infrared spectroscopy. BJOG: an international journal of obstetrics and gynaecology1994;101(1):44‐8. ">Peebles 1994</a>). Uterine tachysystole was found to be associated with a progressive decrease of fetal oxygen saturation (FSpO<sub>2</sub>) (<a href="./references#CD009770-bbs2-0054" title="SimpsonKR , JamesDC . Effects of oxytocin‐induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. American Journal of Obstetrics and Gynecology2008;199(1):34.e1‐.e5. ">Simpson 2008</a>), and with a fall in fetal intracerebral oxygen saturation (<a href="./references#CD009770-bbs2-0047" title="PeeblesDM , SpencerJA , EdwardsAD , WyattJS , ReynoldsEO , CopeM , et al. Relation between frequency of uterine contractions and human fetal cerebral oxygen saturation studied during labour by near infrared spectroscopy. BJOG: an international journal of obstetrics and gynaecology1994;101(1):44‐8. ">Peebles 1994</a>). In one study, five and six or more contractions per 10 minutes for 30 minutes resulted in 20% and 29% fetal oxygen desaturation, respectively (<a href="./references#CD009770-bbs2-0054" title="SimpsonKR , JamesDC . Effects of oxytocin‐induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. American Journal of Obstetrics and Gynecology2008;199(1):34.e1‐.e5. ">Simpson 2008</a>). Importantly, tachysystole over a one‐hour period in active labour can be correlated with a significantly increased risk of fetal acidosis. A study of 1433 women with singleton pregnancies in the Netherlands concluded that increased uterine activity in first and second stage is correlated with a higher incidence of umbilical artery pH of 7.11 or less (<a href="./references#CD009770-bbs2-0031" title="BakkerPC , KurverPH , KuikDJ , VanGeijnHP . Elevated uterine activity increases the risk of fetal acidosis at birth. American Journal of Obstetrics and Gynecology2007;196(4):313. ">Bakker 2007</a>). This can in turn lead to an increase in adverse neonatal sequelae (<a href="./references#CD009770-bbs2-0040" title="HankinsGD , SpeerM . Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. Obstetrics &amp; Gynecology2003;102(3):628‐36. ">Hanskin 2003</a>). </p> </section> <section id="CD009770-sec-0032"> <h3 class="title" id="CD009770-sec-0032">Description of the intervention</h3> <p>Intrauterine fetal resuscitation consists of interventions that aim to increase oxygen delivery to the placenta and enhance fetoplacental perfusion (<a href="./references#CD009770-bbs2-0029" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstetrics &amp; Gynecology2009;114(1):192‐202. ">ACOG 2009</a>). National and international guidelines currently recommend intervention to correct non‐reassuring FHR patterns or suspected fetal distress during labour (<a href="./references#CD009770-bbs2-0029" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstetrics &amp; Gynecology2009;114(1):192‐202. ">ACOG 2009</a>), FHR changes in the presence of excessive uterine activity (<a href="./references#CD009770-bbs2-0049" title="National Collaborating Centre for Women's and Children's Health (UK). Induction of Labour. London: RCOG Press, 2008. ">RCOG 2008</a>), or excessive uterine activity in the absence of FHR changes (<a href="./references#CD009770-bbs2-0058" title="World Health Organization. WHO Recommendations for Induction of Labour. Geneva: World Health Organization, 2011. ">WHO 2011</a>). The available interventions include discontinuation of any labour‐stimulating agents, change of maternal position, administration of supplemental maternal oxygen, and if the abnormal FHR patterns persist, the use of tocolytic agents (<a href="./references#CD009770-bbs2-0029" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstetrics &amp; Gynecology2009;114(1):192‐202. ">ACOG 2009</a>); the latter is the subject of this review. The use of tocolysis for assisting delivery at caesarean section is addressed by another Cochrane Review (<a href="./references#CD009770-bbs2-0037" title="DoddJM , ReidK . Tocolysis for assisting delivery at caesarean section. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD004944.pub2] ">Dodd 2006</a>). </p> <p>There is a wide range of tocolytic agents used acutely during labour for correcting uterine tachysystole, with or without the presence of suspected fetal distress. While studies have predominantly evaluated beta<sub>2</sub> (ß<sub>2</sub>)‐adrenergic receptor agonists (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0030" title="AriasF . Intrauterine resuscitation with terbutaline: a method for the management of acute intrapartum fetal distress. American Journal of Obstetrics and Gynecology1978;131(1):39‐43. ">Arias 1978</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0009" title="BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2001;185(6):S209. BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2002;187(1):235‐8. ">Buhimschi 2002</a>; <a href="./references#CD009770-bbs2-0036" title="DeHeusR , MulderEJ , DerksJB , KurverPH , VanWolfswinkelL , VisserGH . A prospective randomized trial of acute tocolysis in term labour with atosiban or ritodrine. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2008;139(2):139‐45. ">De Heus 2008</a>; <a href="./references#CD009770-bbs2-0016" title="GerrisJ , ThieryM , BogaertM , DeSchaepdryverA . Randomized trial of two beta‐mimetic drugs (ritodrine and fenoterol) in acute intra‐partum tocolysis. European Journal of Clinical Pharmacology1980;18:443‐8. ">Gerris 1980</a>; <a href="./references#CD009770-bbs2-0043" title="IngemarssonI , ArulkumaranS , RatnamSS . Single injection of terbutaline in term labor. I. Effect on fetal pH in cases with prolonged bradycardia. American Journal of Obstetrics and Gynecology1985;153(8):859‐65. ">Ingemarsson 1985</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0048" title="PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐.e6. ">Pullen 2000</a>; <a href="./references#CD009770-bbs2-0051" title="SheybanyS , MurphyJF , EvansD , NewcombeRG , PearsonJF . Ritodrine in the management of fetal distress. BJOG: an international journal of obstetrics and gynaecology1982;89(9):723‐6. ">Sheybany 1982</a>), some have also used magnesium sulphate (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0056" title="Vigil‐De GraciaP , SimitiE , LoraY . Intrapartum fetal distress and magnesium sulfate. International Journal of Gynecology and Obstetrics2000;68(1):3‐6. ">Vigil‐De Gracia 2000</a>), nitric oxide donors (<a href="./references#CD009770-bbs2-0009" title="BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2001;185(6):S209. BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2002;187(1):235‐8. ">Buhimschi 2002</a>; <a href="./references#CD009770-bbs2-0048" title="PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐.e6. ">Pullen 2000</a>), calcium channel blockers (<a href="./references#CD009770-bbs2-0012" title="ChaoA , El‐SayedYY , SapugayAM . Does nifedipine prevent the tachysystole associated with misoprostol induction?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2002;11(4):266‐9. ">Chao 2002</a>), or oxytocin antagonists (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0036" title="DeHeusR , MulderEJ , DerksJB , KurverPH , VanWolfswinkelL , VisserGH . A prospective randomized trial of acute tocolysis in term labour with atosiban or ritodrine. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2008;139(2):139‐45. ">De Heus 2008</a>). Unfortunately, to date, no consistent recommendations on the indications for tocolytic therapy during labour, the preferred type of tocolytic agent, or the optimum dosage of these agents have been available. </p> </section> <section id="CD009770-sec-0033"> <h3 class="title" id="CD009770-sec-0033">How the intervention might work</h3> <p>Acute tocolysis inhibits uterine smooth muscle activity (<a href="./references#CD009770-bbs2-0042" title="HubinontC , DebieveF . Prevention of preterm labour: 2011 update on tocolysis. Journal of Pregnancy2011;2011:941057. ">Hubinont 2011</a>), and has been used on the assumption that such relaxation improves placental perfusion and therefore may enhance fetal oxygenation (<a href="./references#CD009770-bbs2-0053" title="SimpsonK . Intrauterine resuscitation during labor: review of current methods and supportive evidence. Journal of Midwifery &amp; Women's Health2007;52(3):229‐37. ">Simpson 2007</a>). The intervention is employed to either improve fetal status and facilitate vaginal delivery, or as an interim method to improve fetal status whilst preparations for operative delivery are made (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0053" title="SimpsonK . Intrauterine resuscitation during labor: review of current methods and supportive evidence. Journal of Midwifery &amp; Women's Health2007;52(3):229‐37. ">Simpson 2007</a>). It is also possible that an improvement in the FHR trace may reduce caesarean section rates, given that a non‐reassuring fetal heart tracing is one of the leading indications for emergency caesarean section (<a href="./references#CD009770-bbs2-0032" title="BarberE , LundsbergL , BelangerK , PettkerC , FunaiE , IlluzziJ . Contributing indications to the rising cesarean delivery rate. Obstetrics &amp; Gynecology2011;118(1):29‐38. ">Barber 2011</a>). </p> </section> <section id="CD009770-sec-0034"> <h3 class="title" id="CD009770-sec-0034">Why it is important to do this review</h3> <p>In an earlier Cochrane Review on tocolytics for suspected intrapartum fetal distress (<a href="./references#CD009770-bbs2-0059" title="KulierR , HofmeyrGJ . Tocolytics for suspected intrapartum fetal distress. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000035] ">Kulier 2000</a>), betamimetic therapy was associated with a reduction of the number of FHR abnormalities. However the review did not assess whether tocolytics were effective in preventing or treating suspected fetal distress. This new review builds on the work of the <a href="./references#CD009770-bbs2-0059" title="KulierR , HofmeyrGJ . Tocolytics for suspected intrapartum fetal distress. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000035] ">Kulier 2000</a> study and will incorporate new evidence about the effects of different agents on uterine tachysystole which has emerged in recent years. </p> <p>Regardless of advances in surgical and anaesthesia techniques, caesarean delivery is associated with a significantly increased risk of maternal mortality and morbidity (<a href="./references#CD009770-bbs2-0045" title="LumbiganonP , LaopaiboonM , GülmezogluAM , SouzaJP , TaneepanichskulS , RuyanP , et al. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007‐08. Lancet2010;375(9713):490‐9. ">Lumbiganon 2010</a>). Almost three‐quarters of emergency caesarean deliveries were indicated for dystocia or suspected fetal distress (<a href="./references#CD009770-bbs2-0055" title="StjernholmYV , PeterssonK , EnerothE . Changed indications for cesarean sections. Acta Obstetricia et Gynecologica Scandinavica2010;89(1):49‐53. ">Stjernholm 2010</a>; <a href="./references#CD009770-bbs2-0057" title="vonKatterfeldB , LiJ , McNamaraB , LangridgeAT . Perinatal complications and cesarean delivery among foreign‐born and Australian‐born women in Western Australia, 1998‐2006. International Journal of Gynecology and Obstetrics2012;116(2):153‐7. ">von Katterfeld 2011</a>). Proper and timely management of excessive uterine activity during labour is expected to optimise the progress of labour, and reduce unnecessary caesarean deliveries. It is also expected to improve fetal condition, and therefore neonatal condition at birth. </p> <p>The use of tocolytic therapy for uterine tachysystole (with or without accompanying suspected fetal distress) is however, not consistently recommended among clinical guidelines (<a href="./references#CD009770-bbs2-0029" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstetrics &amp; Gynecology2009;114(1):192‐202. ">ACOG 2009</a>; <a href="./references#CD009770-bbs2-0049" title="National Collaborating Centre for Women's and Children's Health (UK). Induction of Labour. London: RCOG Press, 2008. ">RCOG 2008</a>; <a href="./references#CD009770-bbs2-0058" title="World Health Organization. WHO Recommendations for Induction of Labour. Geneva: World Health Organization, 2011. ">WHO 2011</a>). Acknowledging that only low‐quality evidence is currently available, the World Health Organization (WHO) guideline on induction of labour made a weak recommendation of using betamimetic therapy for uterine hyperstimulation during induction of labour (<a href="./references#CD009770-bbs2-0058" title="World Health Organization. WHO Recommendations for Induction of Labour. Geneva: World Health Organization, 2011. ">WHO 2011</a>). The inconsistency in clinical guidelines is presumably associated with inconsistent use of acute tocolysis in routine practice (<a href="./references#CD009770-bbs2-0052" title="SimpsonKR , JamesDC . Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstetrics &amp; Gynecology2005;105(6):1362‐8. ">Simpson 2005</a>). Thus, an updated Cochrane Review will provide a synthesis of the latest evidence which can be used to guide clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009770-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009770-sec-0035"></div> <p>To assess the effects of the use of acute tocolysis during labour for uterine tachysystole or suspected fetal distress, or both, on fetal, maternal and neonatal outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009770-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009770-sec-0036"></div> <section id="CD009770-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009770-sec-0038"> <h4 class="title">Types of studies</h4> <p>We planned to include all published randomised controlled trials (RCTs), including those using a cluster‐RCT design. Due to the small number of identified studies, we decided to include abstracts if they met other eligibility criteria. </p> <p>Studies using a cross‐over or quasi‐randomised design were not eligible in this review.</p> </section> <section id="CD009770-sec-0039"> <h4 class="title">Types of participants</h4> <p> <ul id="CD009770-list-0001"> <li> <p>Women with uterine tachysystole (defined as more than 5 contractions per 10 minutes in 2 consecutive intervals, or as defined by trial authors) without a non‐reassuring fetal heart rate (FHR) pattern. </p> </li> <li> <p>Women with uterine tachysystole with a non‐reassuring FHR pattern.</p> </li> <li> <p>Women with suspected fetal distress, diagnosed by FHR monitoring or fetal scalp pH measurement, and as defined by trial authors, with or without excessive uterine activity. </p> </li> </ul> </p> </section> <section id="CD009770-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009770-list-0002"> <li> <p>Tocolytics (such as beta<sub>2</sub> (ß<sub>2</sub>)‐adrenergic receptor agonists, nitric oxide donors, calcium channel blockers, magnesium sulphate, oxytocin antagonists) versus placebo or no treatment. </p> </li> <li> <p>Comparison of different tocolytic agents.</p> </li> <li> <p>Tocolytics versus other treatments.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD009770-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009770-list-0003"> <li> <p>Perinatal death or severe morbidity (at least one neonatal intensive care unit (NICU) admission for 24 hours or more, neonatal encephalopathy or convulsions). </p> </li> <li> <p>Fetal or neonatal mortality.</p> </li> <li> <p>Caesarean delivery.</p> </li> </ol> </p> </section> <section id="CD009770-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009770-list-0004"> <li> <p>Abnormal FHR, as defined by trial authors.</p> </li> <li> <p>Uterine tachysystole, with or without non‐reassuring FHR patterns.</p> </li> <li> <p>Postpartum haemorrhage (blood loss &gt; 500 mL).</p> </li> <li> <p>Requirement of additional tocolytic agent.</p> </li> <li> <p>Maternal side effects (tachycardia, hypotension, dyspnoea, headache, nausea, syncope) and need to terminate treatment because of side effects. </p> </li> <li> <p>Fetal oxygen saturation (FSpO<sub>2</sub>), measured by an intrauterine FSpO<sub>2</sub> sensor. </p> </li> <li> <p>Five‐minute Apgar score less than seven.</p> </li> <li> <p>Low umbilical artery pH (less than 7.0, or as defined by trial authors).</p> </li> <li> <p>NICU admission.</p> </li> <li> <p>Neonatal encephalopathy.</p> </li> <li> <p>Neonatal convulsions.</p> </li> <li> <p>Meconium‐stained amniotic fluid.</p> </li> <li> <p>Umbilical cord blood base excess/deficit.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009770-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD009770-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched Cochrane Pregnancy and Childbirth's Trials Register by contacting their Information Specialist (2 February 2018). </p> <p>The Register is a database containing over 24,000 reports of controlled trials in the field of pregnancy and childbirth. For full current search methods used to populate Pregnancy and Childbirth's Trials Register, including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this link to the editorial information about <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth</a> in the Cochrane Library and select the '<i><b>Specialized Register'</b> </i> section from the options on the left side of the screen. </p> <p>Briefly, Cochrane Pregnancy and Childbirth's Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD009770-list-0005"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD009770-bbs1-0001" title="">Included studies</a>; <a href="./references#CD009770-bbs1-0002" title="">Excluded studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>), for unpublished, planned and ongoing trial reports (2 February 2018) using the search methods detailed in <a href="./appendices#CD009770-sec-0162">Appendix 1</a>. </p> </section> <section id="CD009770-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies. We did not apply any language or date restrictions. </p> </section> </section> <section id="CD009770-sec-0047"> <h3 class="title" id="CD009770-sec-0047">Data collection and analysis</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD009770-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SL and JV) independently assessed for inclusion all potential studies identified as a result of the search strategy. The abstracts of all studies identified from the search strategy were independently examined to ascertain the studies meeting the inclusion criteria. We obtained full study reports for those with uncertainty in eligibility. We resolved any disagreement through discussion or, if required, we consulted a third review author (JH). </p> </section> <section id="CD009770-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible studies, two review authors (SL and JV) independently extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, consulted a third review author (JH). We entered data into Review Manager software (<a href="./references#CD009770-bbs2-0050" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD009770-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SL and JV) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009770-bbs2-0041" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or by involving a third assessor (JH). </p> <section id="CD009770-sec-0051"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>For each included study, we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD009770-list-0006"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0052"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether the intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. </p> <p>We then assessed the methods as:</p> <p> <ul id="CD009770-list-0007"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes; alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0053"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD009770-list-0008"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0054"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD009770-list-0009"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0055"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data, including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.  Where sufficient information was reported, or could be supplied by the trial authors, we included missing data in the analyses that we undertook. </p> <p>We assessed methods as:</p> <p> <ul id="CD009770-list-0010"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> <p>The extent to which the outcome data were incomplete was assessed as:</p> <p> <ul id="CD009770-list-0011"> <li> <p>less than 5% incomplete outcome data;</p> </li> <li> <p>5% to 9.9% incomplete outcome data;</p> </li> <li> <p>10% to 19.9% incomplete outcome data;</p> </li> <li> <p>more than 20% incomplete outcome data.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0056"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD009770-list-0012"> <li> <p>low risk of bias (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0057"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD009770-list-0013"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD009770-sec-0058"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009770-bbs2-0041" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered that it was likely to impact on the findings.  We planned to explore the impact of the level of bias through undertaking sensitivity analyses, however this was not possible for any of the included studies ‐ see <a href="#CD009770-sec-0070">Sensitivity analysis</a>.  </p> </section> <section id="CD009770-sec-0059"> <h5 class="title">Assessing the quality of the body of evidence using the GRADE approach</h5> <p>We used the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a> in order to assess the quality of the body of evidence relating to the following outcomes for all comparisons. </p> <p> <ol id="CD009770-list-0014"> <li> <p>Perinatal death or severe morbidity (at least one NICU admission for 24 hours or more, neonatal encephalopathy or convulsions). </p> </li> <li> <p>Fetal or neonatal mortality.</p> </li> <li> <p>Caesarean delivery.</p> </li> <li> <p>Five‐minute Apgar score less than seven.</p> </li> <li> <p>Low umbilical artery pH (less than 7.0, or as defined by trial authors).</p> </li> <li> <p>Abnormal FHR, as defined by trial authors.</p> </li> </ol> </p> <p>We used <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5 in order to create 'Summary of findings' tables (<a href="./references#CD009770-bbs2-0050" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We produced a summary of the intervention effect and a measure of quality for each of the above outcomes using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> <section id="CD009770-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009770-sec-0061"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratios (RRs) with 95% confidence intervals (CIs). </p> </section> <section id="CD009770-sec-0062"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference (MD) if outcomes were measured in the same way between trials. We used the standardised mean difference (SMD) to combine trials that measure the same outcome, but used different methods.   </p> </section> </section> <section id="CD009770-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009770-sec-0064"> <h5 class="title">Cluster‐randomised trials</h5> <p>We planned to include cluster‐randomised trials in the analyses along with individually‐randomised trials, however we did not identify any. If, in future updates, we include cluster‐randomised trials, we will adjust their sample sizes by the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009770-bbs2-0041" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>), using an estimate of the intracluster correlation coefficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. </p> <p>We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit. </p> <p>A statistician will be involved in this part of the analysis.</p> </section> </section> <section id="CD009770-sec-0065"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. In future updates, if more eligible studies are included, we will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD009770-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if I² was greater than 30% and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. If we identified substantial heterogeneity (above 30%), we planned to explore it by prespecified subgroup analysis, however we did not identify any. </p> </section> <section id="CD009770-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates, if there are 10 or more studies in the meta‐analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD009770-sec-0068"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager 5 software (<a href="./references#CD009770-bbs2-0050" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect, i.e. where trials were examining the same intervention, and the trials' populations and methods were judged sufficiently similar. </p> <p>If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we detected substantial statistical heterogeneity, we used random‐effects meta‐analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary will be treated as the average range of possible treatment effects and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not combine trials. Where we used random‐effects analyses, we presented the results as the average treatment effect with 95% CIs, and the estimates of Tau² and I². </p> </section> <section id="CD009770-sec-0069"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses, and consider whether an overall summary is meaningful. However, this was not necessary in this review. </p> <p>We planned to carry out the following subgroup analysis.</p> <p> <ol id="CD009770-list-0015"> <li> <p>The type of labour (induced labour or spontaneous labour).</p> </li> <li> <p>The type of tocolytic agents given (ß<sub>2</sub>‐adrenergic receptor agonist, or magnesium sulphate, or nitric oxide donors, or oxytocin antagonist). </p> </li> <li> <p>The indications for tocolysis (therapeutic tocolysis or preventive tocolysis. The latter is defined as tocolysis used for preventing fetal distress in the second stage of labour or at the same time as labour‐stimulating agents are given). </p> </li> </ol> </p> <p>We planned to explore the primary outcomes in subgroup analyses, however available data did not permit subgroup analyses in this review. We will perform planned subgroup analysis in future updates of this review, if appropriate. </p> </section> <section id="CD009770-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analysis to explore the potential effect of study quality on the important outcomes, however the available data did not permit this. We will carry out planned sensitivity analyses in future updates of the review, if appropriate. Sensitivity analysis for trial quality will include high‐quality studies rated as adequate for allocation concealment, to identify whether there are any substantive differences to the pooled result. If we include cluster‐RCTs in our analyses along with the individually‐randomised trials we will also carry out sensitivity analysis to investigate the effect of the randomisation unit. We will restrict all sensitivity analyses to the review's primary outcomes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009770-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009770-sec-0071"></div> <section id="CD009770-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD009770-sec-0073"> <h4 class="title">Results of the search</h4> <p>See: <a href="#CD009770-fig-0001">Figure 1</a> </p> <div class="figure" id="CD009770-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009770-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The search retrieved 40 trial reports to assess. Of these 40 reports, 14 reports of eight studies met the inclusion criteria for the review (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). We excluded 26 reports of 20 studies (<a href="./references#CD009770-bbs2-0009" title="BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2001;185(6):S209. BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2002;187(1):235‐8. ">Buhimschi 2002</a>; <a href="./references#CD009770-bbs2-0010" title="BurkeMS , PorrecoRP , DayD , WatsonJD , HaverkampAD , OrleansM , et al. Intrauterine resuscitation with tocolysis: an alternate month clinical trial. Journal of Perinatology1989;9(3):296‐300. ">Burke 1989</a>; <a href="./references#CD009770-bbs2-0011" title="CampbellJ , AndersonI , ChangA , WoodC . The use of ritodrine in the management of the fetus during the second stage of labour. Australian and New Zealand Journal of Obstetrics and Gynaecology1978;18:110‐3. ">Campbell 1978</a>; <a href="./references#CD009770-bbs2-0012" title="ChaoA , El‐SayedYY , SapugayAM . Does nifedipine prevent the tachysystole associated with misoprostol induction?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2002;11(4):266‐9. ">Chao 2002</a>; <a href="./references#CD009770-bbs2-0013" title="CilliersJBF , SchoonMG , BamRH , NiemandI . A randomised clinical trial to determine the effect of beta‐adrenergic blocking with propranolol on labour. South African Journal of Obstetrics and Gynaecology2013;19(2):53‐5. SchoonMG , CilliersJBF , BamRH , NiemandI . A randomised clinical trial to determine the effect of beta‐adrenergic blocking with propanolol on labour. 20th Conference on Priorities in Perinatal Care in Southern Africa; 2001 March 6‐9; KwaZulu‐Natal, South Africa. 2001. ">Cilliers 2013</a>; <a href="./references#CD009770-bbs2-0014" title="ACTRN12615000319572 . Does sildenafil reduce the risk of fetal distress in labour?. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368057 (first received 9 April 2015). DunnL , FlenadyV , KumarS . Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double‐blind randomised control trial. Journal of Translational Medicine2016;14(1):15. [MEDLINE: 26767411] ">Dunn 2016</a>; <a href="./references#CD009770-bbs2-0015" title="EkbladU , ErkkolaR , UotilaP , KantoJ , PaloP . Ritodrine infusion at term: effects on maternal and fetal prostacyclin, thromboxane and prostaglandin precursor fatty acids. Gynecologic and Obstetric Investigation1988;25:106‐12. ">Ekblad 1988</a>; <a href="./references#CD009770-bbs2-0016" title="GerrisJ , ThieryM , BogaertM , DeSchaepdryverA . Randomized trial of two beta‐mimetic drugs (ritodrine and fenoterol) in acute intra‐partum tocolysis. European Journal of Clinical Pharmacology1980;18:443‐8. ">Gerris 1980</a>; <a href="./references#CD009770-bbs2-0017" title="GoeschenK , FuchsAR , FuchsF , RasmussenAB , RehnstromJV , SalingE . Effect of beta‐mimetic tocolysis on cervical ripening and plasma prostaglandin F2alpha metabolite after endocervical application of prostaglandin E2. Obstetrics &amp; Gynecology1985;65:166‐71. ">Goeschen 1985</a>; <a href="./references#CD009770-bbs2-0018" title="HidakaA , KomatamiM , IkedaH , KitanakaT , OkadaK , SugawaT . A comparative study of intrauterine fetal resuscitation by B‐Stimulant and 02 Inhalation. Asia‐Oceania Journal of Obstetrics and Gynaecology1987;13(2):195‐200. ">Hidaka 1987</a>; <a href="./references#CD009770-bbs2-0019" title="HumphreyM , ChangA , GilbertM , WoodC . The effect of intravenous ritodrine on the acid‐base status of the fetus during the second stage of labour. British Journal of Obstetrics and Gynaecology1975;82:234‐45. ">Humphrey 1975</a>; <a href="./references#CD009770-bbs2-0020" title="KashanianM , AfsharA , ZarrinZ . A comparison between the effect of oxytocin only and oxytocin plus propanolol on the labor (a double blind randomized trial). Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):73. KashanianM , FekratM , ZarrinZ , AnsariNS . A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). Journal of Obstetrics and Gynaecology Research2008;34(3):354‐8. KashanianM , ZarrinZ . A comparison between the effect of oxytocin only and oxytocin plus propanolol on the labor: a double blind randomized trial. Journal of the Kashan University of Medical Sciences2006;10(2):7‐11. KashanianM , ZarrinZ . A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):616‐7. ">Kashanian 2006a</a>; <a href="./references#CD009770-bbs2-0021" title="LipshitzJ , BaillieP . The effects of the fenoterol hydrobromide (Partusisten) aerosol on uterine activity and the cardiovascular system. British Journal of Obstetrics and Gynaecology1976;83:864‐9. ">Lipshitz 1976a</a>; <a href="./references#CD009770-bbs2-0022" title="LipshitzJ , BaillieP . Uterine and cardiovascular effects of beta2‐selective sympathomimetic drugs administered as an intravenous infusion. South African Medical Journal1976;50:1973‐7. ">Lipshitz 1976b</a>; <a href="./references#CD009770-bbs2-0023" title="LipshitzJ , BaillieP , DaveyDA . A comparison of the uterine beta2‐adrenoreceptor selectivity of fenoterol, hexoprenaline, ritodrine and salbutamol. South African Medical Journal1976;50:1969‐72. ">Lipshitz 1976c</a>; <a href="./references#CD009770-bbs2-0024" title="LipshitzJ , LipshitzEM . Uterine and cardiovascular effects of fenoterol and hexoprenaline in prostaglandin F2alpha‐induced labor in humans. Obstetrics &amp; Gynecology1984;63:396‐400. ">Lipshitz 1984</a>; <a href="./references#CD009770-bbs2-0025" title="SharamiSH , MilaniF , TofighiM , SalamtF , Dalil HeiratiSF . Effect of oxytocin plus propranolol on the success of labor augmentation. Journal of Guilan University of Medical Sciences2012;82:57‐64. ">Sharami 2012</a>; <a href="./references#CD009770-bbs2-0026" title="TaylorAVG , BolandJC , MacKenzieIZ . Prostaglandin induced cervical ripening under tocolytic cover in primiparae: results of a double blind placebo controlled trial. British Journal of Obstetrics and Gynaecology1990;97:827‐31. ">Taylor 1990</a>; <a href="./references#CD009770-bbs2-0027" title="TorresR , SantiagoP , RiveraJ , AdamsonsK . Reduction of the duration of induced labor after blockade of myometrial adrenergic beta receptors with propanolol. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):708. ">Torres 2001</a>; <a href="./references#CD009770-bbs2-0028" title="VisserAA , PrinslooST , GiesteiraMVK . Suppression of uterine activity with salbutamol before caesarean section. South African Medical Journal1979;56:1093‐8. ">Visser 1979</a>), </p> </section> <section id="CD009770-sec-0074"> <h4 class="title">Included studies</h4> <p>Eight studies (involving 734 women) met the inclusion criteria (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). The included studies explored a range of tocolytic interventions. </p> <section id="CD009770-sec-0075"> <h5 class="title">Design</h5> <p>All included studies were two‐arm individually‐randomised controlled trials, though none were placebo‐controlled. </p> </section> <section id="CD009770-sec-0076"> <h5 class="title">Sample sizes</h5> <p>Two studies described power calculations in determining their sample sizes (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). The <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a> study randomised 390 compared to the 392 required, whilst the <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a> study enrolled the 110 participants required. No other studies describe power calculations, and sample sizes were generally small, ranging from 26 to 75 participants. </p> </section> <section id="CD009770-sec-0077"> <h5 class="title">Settings</h5> <p>All studies were undertaken in hospital settings, with the majority in high‐income countries including the USA (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>), Austria (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), and Uruguay (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>). One was in South Africa (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>), and one in Sri Lanka (<a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>), upper and lower middle‐income countries, respectively. </p> <p>In all studies, participating facilities had the capacity to perform caesarean section.</p> </section> <section id="CD009770-sec-0078"> <h5 class="title">Participants</h5> <p>Seven studies recruited women with signs of fetal distress on fetal heart rate (FHR) monitoring (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>), or on fetal scalp pH, or both (<a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>). The definition of fetal distress varied between trials (defined by the authors, as outlined in <a href="./references#CD009770-sec-0172" title="">Characteristics of included studies</a>). One of these studies (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>), excluded women with uterine tachysystole by including only women with a uterine contraction pattern of three to five in 10 minutes, whilst the others did not select women based on uterine activity. One study included women who were on an oxytocin infusion for augmentation of labour and who had uterine hyperstimulation, but who did not have signs of fetal distress on FHR monitoring (<a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>). </p> <p>Four studies recruited women only when fetal distress had not resolved with "conservative" measures, which usually included maternal repositioning, intravenous (IV) fluids, oxygen, cessation of labour‐augmenting agents and the option of amnioinfusion (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). Four studies included women for whom the decision had already been made to deliver by caesarean section due to fetal distress (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). </p> <p>In terms of gestational age, two studies included women at "term" (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>), one included women at ≥ 38 weeks' gestation (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), one at &gt; 35 weeks' gestation (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>), and one at 32 to 42 weeks' gestation (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). Three did not specify a gestational age for inclusion (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>), though the mean gestational ages for participants in the <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> and <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a> studies fell between 38 and 40 weeks. All but one study required that included women be in active labour, with the only exception being the <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a> study. </p> <p>Only one study stated a cephalic presentation as an inclusion criterion (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>), and three included a singleton pregnancy as an inclusion criterion (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). Whilst not stated as inclusion criteria, the <a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a> study only included women with a singleton pregnancy in a cephalic presentation at the time of randomisation. </p> <p>Most studies excluded participants with severe maternal disease (e.g. pre‐eclampsia, cardiac disease, metabolic diseases, hyperthyroidism, antepartum haemorrhage, chorioamnionitis), or fetal or placental abnormalities (e.g. intrauterine growth restriction, fetal malformations, placental abruption) (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). </p> </section> <section id="CD009770-sec-0079"> <h5 class="title">Interventions and comparisons</h5> <p>All eight studies examined a selective ß<sub>2</sub>‐adrenergic agonist, however the type of agonist varied between studies. Two studies compared administration of a selective ß<sub>2</sub>‐adrenergic agonist (IV hexoprenaline or subcutaneous terbutaline) to no tocolytic agent whilst awaiting emergency delivery (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>). Three studies evaluated subcutaneous terbutaline (a selective ß<sub>2</sub>‐adrenergic agonist), with one comparing it to IV magnesium sulphate (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>), one comparing it to no tocolytic agent, whilst awaiting emergency delivery (<a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>), and the third comparing two protocols: terbutaline with continuation of an oxytocin infusion compared to cessation of the oxytocin infusion without administration of a tocolytic agent (<a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>). A fourth study compared IV terbutaline to IV nitroglycerin (a nitric oxide donor) (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). One study compared IV atosiban (an oxytocin inhibitor) to IV hexoprenaline (a selective ß<sub>2</sub>‐adrenergic agonist) (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), one compared IV salbutamol (a selective ß<sub>2</sub>‐adrenergic agonist) to sublingual nifedipine (a calcium channel blocker) (<a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>), and one compared IV fenoterol (a selective ß<sub>2</sub>‐adrenergic agonist) to emergency delivery (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>). </p> </section> <section id="CD009770-sec-0080"> <h5 class="title">Outcomes</h5> <p>Primary outcomes for this review included perinatal death or severe morbidity, fetal or neonatal mortality, and caesarean section delivery. Only one study addressed the outcome of perinatal death or severe morbidity (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>). Three studies reported on fetal or neonatal mortality (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>), though across all three studies there were only two perinatal deaths. Caesarean section rates were reported in four studies (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). Several studies did not report on caesarean section rates, as the decision was made prior to randomisation to deliver all participants by caesarean section. </p> <p>Secondary outcomes for the review included neonatal, maternal and labour outcomes.</p> <p>The <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a> study did not present data for any primary or secondary outcomes in a format that could be analysed for this review. All other studies addressed umbilical artery pH, although cut‐offs used varied from 7.00 to 7.20, and all except the <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> study reported on five‐minute Apgar scores less than seven. Two studies reported umbilical artery base excess (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>), whilst none reported on intrauterine fetal oxygen saturation (FSpO<sub>2</sub>). Three studies reported on rates of admission to neonatal intensive care units (NICUs) (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>). Five studies reported if there was an abnormal FHR tracing following treatment, with the individual study outcomes including whether the FHR pattern improved or remained unchanged (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>), or whether there was a complete resolution of the non‐reassuring FHR pattern within 10 minutes and whether such a pattern recurred (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). Two studies did not prespecify this outcome but reported it: the <a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a> study reported on the number of participants with "recovery to normal fetal heart rate", and the <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a> study reported on whether FHR decelerations were detected after treatment, and whether they had changed in their amplitude and frequency. We considered this spectrum of reporting on FHR abnormalities by the review authors to satisfy the prespecified outcome of "abnormal FHR, as defined by study authors". Two studies reported on the presence of meconium‐stained liquor (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). Two studies reported on rates of uterine tachysystole following treatment, defined by the <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a> study as resolution of tachysystole within 10 minutes and by the <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> study as the mean difference (MD) in Montevideo units in the 10 minutes before and the 10 minutes following treatment. One study reported on rates of postpartum haemorrhage (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>), though the <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> study did report the mean estimated blood loss for participants. Two studies reported on maternal side effects. This was defined by the <a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a> study as palpitations or tachycardia, whilst the <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a> study reported only whether "side effects" were noticed. Only one study reported on whether a subsequent tocolytic was required (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). No studies reported rates of neonatal encephalopathy or neonatal convulsions. </p> </section> <section id="CD009770-sec-0081"> <h5 class="title">Sources of funding</h5> <p>Atosiban was supplied by Ferring Pharmaceuticals for the <a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a> study, however sources of funding for the other studies was otherwise not disclosed (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). </p> </section> <section id="CD009770-sec-0082"> <h5 class="title">Declarations of interest</h5> <p>The authors of the <a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a> study reported no personal financial support; there was no comment on other potential conflicts of interest. No other trials included declarations on conflicts of interest (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). </p> </section> </section> <section id="CD009770-sec-0083"> <h4 class="title">Excluded studies</h4> <p>After assessment of study eligibility, we excluded 20 studies. The main reasons for exclusion was that the study did not include participants with uterine tachysystole or suspected fetal distress (13 studies: <a href="./references#CD009770-bbs2-0009" title="BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2001;185(6):S209. BuhimschiCS , BuhimschiIA , MalinowAM , WeinerCP . Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. American Journal of Obstetrics and Gynecology2002;187(1):235‐8. ">Buhimschi 2002</a>; <a href="./references#CD009770-bbs2-0011" title="CampbellJ , AndersonI , ChangA , WoodC . The use of ritodrine in the management of the fetus during the second stage of labour. Australian and New Zealand Journal of Obstetrics and Gynaecology1978;18:110‐3. ">Campbell 1978</a>; <a href="./references#CD009770-bbs2-0012" title="ChaoA , El‐SayedYY , SapugayAM . Does nifedipine prevent the tachysystole associated with misoprostol induction?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2002;11(4):266‐9. ">Chao 2002</a>; <a href="./references#CD009770-bbs2-0013" title="CilliersJBF , SchoonMG , BamRH , NiemandI . A randomised clinical trial to determine the effect of beta‐adrenergic blocking with propranolol on labour. South African Journal of Obstetrics and Gynaecology2013;19(2):53‐5. SchoonMG , CilliersJBF , BamRH , NiemandI . A randomised clinical trial to determine the effect of beta‐adrenergic blocking with propanolol on labour. 20th Conference on Priorities in Perinatal Care in Southern Africa; 2001 March 6‐9; KwaZulu‐Natal, South Africa. 2001. ">Cilliers 2013</a>; <a href="./references#CD009770-bbs2-0014" title="ACTRN12615000319572 . Does sildenafil reduce the risk of fetal distress in labour?. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368057 (first received 9 April 2015). DunnL , FlenadyV , KumarS . Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double‐blind randomised control trial. Journal of Translational Medicine2016;14(1):15. [MEDLINE: 26767411] ">Dunn 2016</a>; <a href="./references#CD009770-bbs2-0015" title="EkbladU , ErkkolaR , UotilaP , KantoJ , PaloP . Ritodrine infusion at term: effects on maternal and fetal prostacyclin, thromboxane and prostaglandin precursor fatty acids. Gynecologic and Obstetric Investigation1988;25:106‐12. ">Ekblad 1988</a>; <a href="./references#CD009770-bbs2-0016" title="GerrisJ , ThieryM , BogaertM , DeSchaepdryverA . Randomized trial of two beta‐mimetic drugs (ritodrine and fenoterol) in acute intra‐partum tocolysis. European Journal of Clinical Pharmacology1980;18:443‐8. ">Gerris 1980</a>; <a href="./references#CD009770-bbs2-0019" title="HumphreyM , ChangA , GilbertM , WoodC . The effect of intravenous ritodrine on the acid‐base status of the fetus during the second stage of labour. British Journal of Obstetrics and Gynaecology1975;82:234‐45. ">Humphrey 1975</a>; <a href="./references#CD009770-bbs2-0021" title="LipshitzJ , BaillieP . The effects of the fenoterol hydrobromide (Partusisten) aerosol on uterine activity and the cardiovascular system. British Journal of Obstetrics and Gynaecology1976;83:864‐9. ">Lipshitz 1976a</a>; <a href="./references#CD009770-bbs2-0022" title="LipshitzJ , BaillieP . Uterine and cardiovascular effects of beta2‐selective sympathomimetic drugs administered as an intravenous infusion. South African Medical Journal1976;50:1973‐7. ">Lipshitz 1976b</a>; <a href="./references#CD009770-bbs2-0023" title="LipshitzJ , BaillieP , DaveyDA . A comparison of the uterine beta2‐adrenoreceptor selectivity of fenoterol, hexoprenaline, ritodrine and salbutamol. South African Medical Journal1976;50:1969‐72. ">Lipshitz 1976c</a>; <a href="./references#CD009770-bbs2-0026" title="TaylorAVG , BolandJC , MacKenzieIZ . Prostaglandin induced cervical ripening under tocolytic cover in primiparae: results of a double blind placebo controlled trial. British Journal of Obstetrics and Gynaecology1990;97:827‐31. ">Taylor 1990</a>; <a href="./references#CD009770-bbs2-0027" title="TorresR , SantiagoP , RiveraJ , AdamsonsK . Reduction of the duration of induced labor after blockade of myometrial adrenergic beta receptors with propanolol. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):708. ">Torres 2001</a>), or no tocolytic intervention was used (three studies: <a href="./references#CD009770-bbs2-0017" title="GoeschenK , FuchsAR , FuchsF , RasmussenAB , RehnstromJV , SalingE . Effect of beta‐mimetic tocolysis on cervical ripening and plasma prostaglandin F2alpha metabolite after endocervical application of prostaglandin E2. Obstetrics &amp; Gynecology1985;65:166‐71. ">Goeschen 1985</a>; <a href="./references#CD009770-bbs2-0020" title="KashanianM , AfsharA , ZarrinZ . A comparison between the effect of oxytocin only and oxytocin plus propanolol on the labor (a double blind randomized trial). Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):73. KashanianM , FekratM , ZarrinZ , AnsariNS . A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). Journal of Obstetrics and Gynaecology Research2008;34(3):354‐8. KashanianM , ZarrinZ . A comparison between the effect of oxytocin only and oxytocin plus propanolol on the labor: a double blind randomized trial. Journal of the Kashan University of Medical Sciences2006;10(2):7‐11. KashanianM , ZarrinZ . A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):616‐7. ">Kashanian 2006a</a>; <a href="./references#CD009770-bbs2-0025" title="SharamiSH , MilaniF , TofighiM , SalamtF , Dalil HeiratiSF . Effect of oxytocin plus propranolol on the success of labor augmentation. Journal of Guilan University of Medical Sciences2012;82:57‐64. ">Sharami 2012</a>). Four studies were not RCTs (<a href="./references#CD009770-bbs2-0010" title="BurkeMS , PorrecoRP , DayD , WatsonJD , HaverkampAD , OrleansM , et al. Intrauterine resuscitation with tocolysis: an alternate month clinical trial. Journal of Perinatology1989;9(3):296‐300. ">Burke 1989</a>; <a href="./references#CD009770-bbs2-0018" title="HidakaA , KomatamiM , IkedaH , KitanakaT , OkadaK , SugawaT . A comparative study of intrauterine fetal resuscitation by B‐Stimulant and 02 Inhalation. Asia‐Oceania Journal of Obstetrics and Gynaecology1987;13(2):195‐200. ">Hidaka 1987</a>; <a href="./references#CD009770-bbs2-0024" title="LipshitzJ , LipshitzEM . Uterine and cardiovascular effects of fenoterol and hexoprenaline in prostaglandin F2alpha‐induced labor in humans. Obstetrics &amp; Gynecology1984;63:396‐400. ">Lipshitz 1984</a>; <a href="./references#CD009770-bbs2-0028" title="VisserAA , PrinslooST , GiesteiraMVK . Suppression of uterine activity with salbutamol before caesarean section. South African Medical Journal1979;56:1093‐8. ">Visser 1979</a>). </p> <section id="CD009770-sec-0084"> <h5 class="title">Ongoing studies</h5> <p>We did not identify any ongoing studies.</p> </section> </section> </section> <section id="CD009770-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD009770-fig-0002">Figure 2</a> and <a href="#CD009770-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009770-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009770-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009770-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009770-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009770-sec-0086"> <h4 class="title">Allocation</h4> <section id="CD009770-sec-0087"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>Of the eight included trials, we assessed six as having adequate randomisation methods. Three studies used computer‐generated randomisation in blocks of 10 (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>), blocks of 20 (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>), or by simple randomisation (<a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>). Two studies used a random number table (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). One study used "randomly generated numbers" (<a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>). The method of randomisation was unclear in two studies: one described randomisation as being performed by "treatment boxes" without an explanation of what these were (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), whilst the other did not describe the randomisation process (<a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). </p> </section> <section id="CD009770-sec-0088"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>We rated two of the included studies as unclear for allocation concealment (<a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). We judged the remainder to have a low risk of bias. Two studies used sealed opaque envelopes (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>), whilst two used sealed envelopes that were not specified to be opaque (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>). One had the allocation stored offsite (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), and one used a concealed chart that was only available to the labour and delivery nurse preparing the study medication (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). </p> </section> </section> <section id="CD009770-sec-0089"> <h4 class="title">Blinding</h4> <section id="CD009770-sec-0090"> <h5 class="title">Blinding of participants and personnel (checking for possible performance bias)</h5> <p>Blinding of participants was unclear or not discussed in three studies (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). There was a high risk of bias in four studies, in which blinding was not discussed and the interventions were dissimilar enough that the allocation was likely known to participants and personnel (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>). There was a low risk of bias in one study in which women and personnel (except for the nurse preparing the medication) were blinded to the treatment group and the interventions appeared similar (<a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). </p> </section> <section id="CD009770-sec-0091"> <h5 class="title">Blinding of outcome assessment (checking for possible detection bias)</h5> <p>Blinding of outcome assessors was unclear or not described in four reports (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). We also judged the <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a> study to have an unclear risk of bias, as the authors described blinding of neonatologists (who assessed the Apgar score) but did not discuss who assessed the other neonatal outcomes or whether there was any blinding for maternal outcome assessment. We judged one study to have a high risk of bias in outcome assessment as the authors did not discuss blinding (<a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006)</a>, and all participants were observed until delivery by the primary investigator. We assessed two studies to be at low risk of detection bias (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). </p> </section> </section> <section id="CD009770-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p>We were unable to assess attrition in one study (<a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a>). The risk of incomplete outcome data was high in the <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a> study, which had incomplete data for some outcomes but did not provide any justification for this. We judged the remaining studies to have a low risk of attrition bias with low rates of attrition and no differences between groups in terms of characteristics and numbers lost to follow‐up (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>). </p> </section> <section id="CD009770-sec-0093"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of reporting bias to be high for one study due to a combination of factors (<a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a>): we could not locate the study protocol, making it difficult to assess how outcomes were defined before and after the trial; there were also some outcomes that were reported as significant in the text without supporting data, as well as a non‐prespecified "special" subgroup analysis. We judged the risk of reporting bias as unclear in the <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a> and <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a> studies as outcomes were not clearly prespecified, and judged all other included studies as low risk of bias (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a>), with reported outcomes being consistent with prespecified definitions. </p> </section> <section id="CD009770-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p>The sample sizes in the included trials were generally very small, which may have reduced the sensitivity of the studies to detect rarer outcomes. </p> <p>We judged the <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a> study to be at high risk of other bias as it effectively introduced an additional inclusion criteria in the study design by including only those women who had electronic FHR monitoring. In their study, this was only used in women who were at a higher risk and had at least one of: previous perinatal demise; maternal age greater than 40; pathologies during pregnancy; alterations in fetal growth and development; dystocic labour; gestational age greater than 41 weeks; prelabour rupture of membranes; or antepartum haemorrhage in the third trimester. </p> <p><a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a> did not clearly define the management of the comparison group in their paper, however we presumed that the comparison group did not receive medication whilst awaiting delivery. In addition, the study did not prespecify cut‐off values for their study outcomes, however, the values used were clinically reasonable ‐ as assessed this study as having an 'unclear' risk of bias. There was limited information in the trial report by <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a> and we assessed this study as having an 'unclear' risk of other bias. </p> <p>We assessed <a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>; <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>; <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>; <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a> and <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a> as having a 'low' risk of other bias. </p> <p><a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> and <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a> studies did not prespecify cut‐off values for their study outcomes, however those used were clinically reasonable. Only one study specified authors' conflicts of interests and sources of funding (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), with atosiban being provided by Ferring pharmaceuticals. The <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> study was supported in part by the Vicksburg Hospital Medical Foundation. No other studies reported on their sources of funding or support or any potential conflicts of interest. </p> </section> </section> <section id="CD009770-sec-0095"> <h3 class="title" id="CD009770-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD009770-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings for selective ß<sub>2</sub>‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</a>; <a href="./full#CD009770-tbl-0002"><b>Summary of findings 2</b> Summary of findings for IV atosiban versus IV hexoprenaline</a>; <a href="./full#CD009770-tbl-0003"><b>Summary of findings 3</b> Summary of findings for IV fenoterol bromhydrate versus emergency delivery</a>; <a href="./full#CD009770-tbl-0004"><b>Summary of findings 4</b> Summary of findings for IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</a>; <a href="./full#CD009770-tbl-0005"><b>Summary of findings 5</b> Summary of findings for subcutaneous terbutaline versus IV magnesium sulphate</a>; <a href="./full#CD009770-tbl-0006"><b>Summary of findings 6</b> Summary of findings for subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent</a>; <a href="./full#CD009770-tbl-0007"><b>Summary of findings 7</b> Summary of findings for subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</a>; <a href="./full#CD009770-tbl-0008"><b>Summary of findings 8</b> Summary of findings for IV terbutaline versus IV nitroglycerin</a> </p> <p>We included nine reports of eight studies (involving 734 women) in this review, however all but one of the comparisons (comparison 1) are based on data from single studies, most with small sample sizes. </p> <p>The GRADE outcomes included in this review were:</p> <p> <ol id="CD009770-list-0016"> <li> <p>perinatal death or severe morbidity (at least one NICU admission for 24 hours or more, neonatal encephalopathy or convulsions); </p> </li> <li> <p>fetal or neonatal mortality;</p> </li> <li> <p>caesarean delivery;</p> </li> <li> <p>five‐minute Apgar score less than seven;</p> </li> <li> <p>low umbilical artery pH (less than 7.0 or as defined by trial authors);</p> </li> <li> <p>abnormal FHR, as defined by trial authors.</p> </li> </ol> </p> <p>Where the results for a given outcome are not reported for individual comparisons, the included trial(s) did not report on that outcome. </p> <section id="CD009770-sec-0096"> <h4 class="title">Selective ß<sub>2</sub>‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery </h4> <p>Two studies (involving 57 women) compared a selective ß<sub>2</sub>‐adrenergic agonist to no tocolytic agent after the decision to proceed to urgent caesarean section had been made. The <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a> study included women in active labour, at or beyond a gestational age of 35 weeks, for whom the decision had been made to deliver by caesarean section for fetal distress. Women were randomised to receiving 10 µg of IV hexoprenaline or no tocolytic medication whilst awaiting delivery. The <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a> study included women in labour with signs of fetal distress that had not responded to conservative measures and with a fetal scalp pH less than 7.25. Women were randomised to receiving 250 µg of subcutaneous terbutaline or no tocolytic medication whilst preparations for urgent caesarean section were being made. </p> <section id="CD009770-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0098"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>Neither of the studies reported on this outcome.</p> </section> <section id="CD009770-sec-0099"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no perinatal deaths in the study by <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a>. Two stillbirths were reported in the <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a> study, both of which occurred in the control group. One was discovered to have gross hydrocephalus at the time of delivery, and the second had been referred with fetal distress from a peripheral clinic and was delivered vaginally after 55 minutes whilst awaiting caesarean delivery (risk ratio (RR) 0.23, 95% confidence interval (CI) 0.01 to 4.55; 2 studies, 57 women; <a href="./references#CD009770-fig-0004" title="">Analysis 1.1</a>). We determined the GRADE quality of evidence to be low, as we downgraded two levels for imprecision (<a href="./full#CD009770-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009770-sec-0100"> <h6 class="title">Caesarean delivery</h6> <p>The decision to deliver by caesarean section had been made for all women in these studies prior to inclusion and randomisation, and so we were unable to address this outcome in this analysis. </p> </section> </section> <section id="CD009770-sec-0101"> <h5 class="title">Secondary outcomes</h5> <p>We are uncertain about the effect of the intervention on the rate of <b>five‐minute Apgar scores less than seven</b> (RR 0.20, 95% CI 0.02 to 1.57; 2 studies, 55 women; low‐quality evidence; <a href="./references#CD009770-fig-0005" title="">Analysis 1.2</a>). There were no cases of five‐minute Apgar scores less than seven in the tocolysis group compared to two cases in the group that did not receive tocolysis. There were no data available regarding <b>umbilical artery pH</b> . There were probably fewer babies in the treatment group that had <b>no improvement in FHR tracing</b> compared to the control group (average RR 0.28, 95% CI 0.08 to 0.95; Tau<sup>2</sup> = 0.48, I<sup>2</sup> = 57%, 2 studies, 43 women; moderate‐quality evidence; <a href="./references#CD009770-fig-0006" title="">Analysis 1.3</a>) (non‐prespecified outcome). </p> </section> </section> <section id="CD009770-sec-0102"> <h4 class="title">IV atosiban versus IV hexoprenaline</h4> <p>One study involving 26 women, compared atosiban, an oxytocin antagonist, to hexoprenaline, a selective ß<sub>2</sub>‐adrenergic agonist (<a href="./references#CD009770-bbs2-0001" title="AfscharP , SchollW , BaderA , BauerM , WinterR . A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG: an international journal of obstetrics and gynaecology2004;111(4):316‐8. ">Afschar 2004</a>), for the management of fetal distress. Women in labour beyond 38 weeks' gestation with a severe fetal bradycardia (&lt; 80 bpm for more than 3 minutes) were randomised to receive either 6.75 mg of IV atosiban or 5 µg of IV hexoprenaline. </p> <section id="CD009770-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0104"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>One infant in the IV hexoprenaline group was admitted to the NICU for &gt; 24 hours following delivery by forceps, and was discharged well five days later (RR 0.33, 95% CI 0.01 to 7.50; low‐quality evidence; <a href="./references#CD009770-fig-0007" title="">Analysis 2.1</a>). </p> </section> <section id="CD009770-sec-0105"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no perinatal deaths in either group (<a href="./references#CD009770-fig-0008" title="">Analysis 2.2</a>). The effect was not estimable, and the quality of evidence was low. </p> </section> <section id="CD009770-sec-0106"> <h6 class="title">Caesarean delivery</h6> <p>One infant in the IV hexoprenaline group was delivered by caesarean section, and none in the IV atosiban group (RR 0.33, 95% CI 0.01 to 7.50; low‐quality evidence; <a href="./references#CD009770-fig-0009" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD009770-sec-0107"> <h5 class="title">Secondary outcomes</h5> <p>No infants in either group had <b>five‐minute Apgar scores less than seven</b> (<a href="./references#CD009770-fig-0010" title="">Analysis 2.4</a>). The effect was not estimable, and the quality of evidence was very low; it is uncertain whether the intervention has an effect on this outcome. </p> <p>There were no differences detected between women treated with atosiban compared to those treated with hexoprenaline in terms of the <b>mean umbilical artery pH</b> (mean difference (MD) 0.00 pH, 95% CI ‐0.05 to 0.05; low‐quality evidence; <a href="./references#CD009770-fig-0011" title="">Analysis 2.5</a>), the rate of <b>abnormal FHR tracings</b> (RR 3.00, 95% CI 0.13 to 67.51; low‐quality evidence; <a href="./references#CD009770-fig-0012" title="">Analysis 2.6</a>), or the number of <b>admissions to the NICU</b> (RR 0.33, 95% CI 0.01 to 7.50; <a href="./references#CD009770-fig-0014" title="">Analysis 2.8</a>). Only one case in the atosiban group had an abnormal FHR tracing compared to none in the hexoprenaline group, whilst one infant in the hexoprenaline group was admitted to the NICU compared to none in the atosiban group. Women who received atosiban were less likely to experience <b>maternal side effects</b> (tachycardia or palpitations) than those who received hexoprenaline (RR 0.10, 95% CI 0.01 to 0.67; <a href="./references#CD009770-fig-0013" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD009770-sec-0108"> <h4 class="title">IV fenoterol bromhydrate versus emergency delivery</h4> <p>The <a href="./references#CD009770-bbs2-0002" title="BriozzoL , MartinezA , NozarM , FiolV , PonsJ , AlonsoJ . Tocolysis and delayed delivery versus emergency delivery in cases of non‐reassuring fetal status during labor. Journal of Obstetrics and Gynaecology Research2007;33(3):266‐73. ">Briozzo 2007</a> study, involving 390 women, compared fenoterol, a selective ß<sub>2</sub>‐adrenergic agonist, to emergency delivery as soon as possible for the management of fetal distress. Women in labour at term who had a fetus in a cephalic presentation and who did not have uterine tachysystole were eligible for inclusion in the event of a non‐reassuring FHR tracing without an identified reversible cause. Women were randomised to receive intrauterine fetal resuscitation with an IV infusion of fenoterol (0.1 mg/minute, titrated according to response) or emergency delivery (either caesarean section or instrumental vaginal delivery, depending on the clinical scenario). Those in the fenoterol group were reassessed after 10 minutes based on uterine contractility and FHR tracings: if the fetal situation remained unchanged or had worsened, the intervention was considered ineffective and emergency delivery was performed as soon as possible; if the fetal situation had improved, the intervention was considered effective and the FHR tracing and uterine activity was monitored for a further 20 minutes before performing emergency delivery. </p> <section id="CD009770-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0110"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>There were no data reported for perinatal death or severe morbidity.</p> </section> <section id="CD009770-sec-0111"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no data reported for fetal or neonatal mortality.</p> </section> <section id="CD009770-sec-0112"> <h6 class="title">Caesarean delivery</h6> <p>Fenoterol probably increases the risk of caesarean delivery compared to emergency delivery (RR 1.12, 95% CI 1.04 to 1.22; moderate‐quality evidence; <a href="./references#CD009770-fig-0015" title="">Analysis 3.1</a>). Of those in the emergency delivery group who were not delivered by caesarean section, 19 (9.6%) were delivered by spontaneous vaginal birth and 19 (9.6%) by forceps. In the fenoterol group, nine (4.7%) were delivered by spontaneous vaginal birth and nine (4.7%) by forceps. The authors attributed this to the fact that fenoterol diminished uterine contractility due to its tocolytic effect, which was proposed to reduce the likelihood of vaginal delivery. </p> </section> </section> <section id="CD009770-sec-0113"> <h5 class="title">Secondary outcomes</h5> <p>Fenoterol may have little or no effect on the risk of <b>five‐minute Apgar scores less than seven</b> (RR 1.28, 95% CI 0.35 to 4.68; low‐quality evidence; <a href="./references#CD009770-fig-0016" title="">Analysis 3.2</a>), or on the rate of <b>umbilical artery pH less than 7.1</b> (RR 0.68, 95% CI 0.44 to 1.05; low‐quality evidence; <a href="./references#CD009770-fig-0017" title="">Analysis 3.3</a>), or <b>umbilical artery base excess &lt; ‐12</b> (RR 0.67, 95% CI 0.46 to 1.00; <a href="./references#CD009770-fig-0018" title="">Analysis 3.4</a>). No data were available regarding <b>abnormal FHR</b> . Infants of women in the fenoterol group were less likely to need <b>admission to the NICU</b> than those who were randomised to emergency delivery (RR 0.47, 95% CI 0.27 to 0.81; <a href="./references#CD009770-fig-0019" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD009770-sec-0114"> <h4 class="title">IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</h4> <p>The <a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a> study, involving 37 women, compared IV hexoprenaline, a selective ß<sub>2</sub>‐adrenergic agonist, to no tocolytic agent in women awaiting emergency delivery for the management of fetal distress. The study included women beyond 35 weeks' gestation who were in active labour, and for whom a decision had been made to deliver by caesarean section due to fetal distress based on FHR tracing. Once randomised, women received either hexoprenaline or no tocolytic whilst awaiting caesarean section ‐ the randomisation‐to‐delivery interval was not significantly different between the groups. </p> <section id="CD009770-sec-0115"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0116"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>There were no data reported for perinatal death or severe morbidity.</p> </section> <section id="CD009770-sec-0117"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were two fetal deaths in the group that did not receive any tocolytic agent (RR 0.23, 95% CI 0.01 to 4.55; low‐quality evidence; <a href="./references#CD009770-fig-0020" title="">Analysis 4.1</a>) ‐ one of these was found to have gross hydrocephalus at the time of delivery, and the other was stillborn by vaginal delivery after 55 minutes whilst awaiting caesarean section after being transferred from a peripheral facility with fetal distress. There were no neonatal deaths in either group. </p> </section> <section id="CD009770-sec-0118"> <h6 class="title">Caesarean delivery</h6> <p>The rate of caesarean delivery was not reported in this study, however women were only randomised once the decision had already been made to deliver by caesarean section. There was one vaginal delivery reported in the group that did not receive a tocolytic agent, which was the stillborn that delivered whilst awaiting caesarean section. </p> </section> </section> <section id="CD009770-sec-0119"> <h5 class="title">Secondary outcomes</h5> <p>There were two babies with Apgar scores below seven at five minutes (RR 0.24, 95% CI 0.01 to 4.57; low‐quality evidence; <a href="./references#CD009770-fig-0021" title="">Analysis 4.2</a>), with both occurring in the group that received no tocolytic. </p> <p>There was little or no difference in the incidence of <b>umbilical artery pH less than 7.2</b> (RR 0.64, 95% CI 0.30 to 1.35; low‐quality evidence; <a href="./references#CD009770-fig-0022" title="">Analysis 4.3</a>). There was probably a reduced likelihood of there being <b>no improvement in the FHR tracing</b> (non‐prespecified outcome) in the IV hexoprenaline group (RR 0.43, 95% CI 0.21 to 0.88; moderate‐quality evidence; <a href="./references#CD009770-fig-0023" title="">Analysis 4.4</a>). There was no clear difference in the incidence of <b>umbilical artery base excess &lt; ‐10</b> (RR 0.43, 95% CI 0.13 to 1.37; <a href="./references#CD009770-fig-0025" title="">Analysis 4.6</a>). There was just one <b>admissions to the NICU,</b> in the IV hexoprenaline group (RR 3.50, 95% CI 0.15 to 80.71; <a href="./references#CD009770-fig-0026" title="">Analysis 4.7</a>). The incidence of <b>meconium‐stained amniotic fluid</b> was less likely in the hexoprenaline group (3/17) compared to the no tocolytic control (12/19) (RR 0.28, 95% CI 0.09 to 0.83; <a href="./references#CD009770-fig-0024" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD009770-sec-0120"> <h4 class="title">Subcutaneous terbutaline versus IV magnesium sulphate</h4> <p>Two reports of one study involving 46 women, compared subcutaneous terbutaline, a selective ß<sub>2</sub>‐adrenergic agonist, to IV magnesium sulphate for the management of fetal distress (<a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a>). The study included women who were in active labour with signs of fetal distress which had not responded to conventional approaches (oxytocic discontinuation, fluid bolus, positional change, oxygen or amnioinfusion), and for whom the decision had been made to deliver by caesarean section. Eligible women were randomised to receive 250 µg of subcutaneous terbutaline or a 4 g bolus of IV magnesium sulphate, with caesarean section commenced within 15 minutes of receiving the study drug. </p> <section id="CD009770-sec-0121"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0122"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>There were no data available to analyse perinatal death or severe morbidity.</p> </section> <section id="CD009770-sec-0123"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no data available to analyse fetal or neonatal mortality.</p> </section> <section id="CD009770-sec-0124"> <h6 class="title">Caesarean delivery</h6> <p>All women in this study were delivered by caesarean section; participants were only randomised once the decision had been made for delivery by caesarean section, and this was performed within 15 minutes of the tocolytic drug in all cases. Therefore it was not possible to assess the impact of the intervention on caesarean section rate. </p> </section> </section> <section id="CD009770-sec-0125"> <h5 class="title">Secondary outcomes</h5> <p>There were no data available regarding <b>five‐minute Apgar scores</b>. We are uncertain about the effects of terbutaline or magnesium sulphate on the risk of umbilical artery pH less than 7.2 (RR 0.29, 95% CI 0.07 to 1.23; very low‐quality evidence; <a href="./references#CD009770-fig-0027" title="">Analysis 5.1</a>), or the likelihood of <b>resolution of fetal distress</b> (non‐prespecified outcome) (RR 1.31, 95% CI 0.97 to 1.77; very low‐quality evidence; <a href="./references#CD009770-fig-0028" title="">Analysis 5.2</a>). Given the quality of the evidence, it is uncertain whether the intervention reduces or increases the likelihood of these outcomes. The <a href="./references#CD009770-bbs2-0004" title="MagannEF , ClevelandRS , DockeryJR , ChauhanSP , MartinJN , MorrisonJC . Acute tocolysis for fetal distress: terbutaline vs magnesium sulphate. Australian and New Zealand Journal of Obstetrics and Gynaecology1993;33:362‐4. MagannEF , ClevelandRS , DockeryJR , ChauhanSP , NormanPH , MartinJN , et al. Acute tocolysis for fetal distress: terbutaline vs magnesium sulfate. 41st Annual Clinical Meeting of The American College of Obstetricians and Gynaecologists; 1993 May 3‐6; USA. 1993:13. MagannEF , NormanPF , BassJD , ChauhanSP , MatinJN , MorrisonJC . Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline vs magnesium sulfate. International Journal of Obstetric Anesthesia1995;4:140‐4. ">Magann 1993</a> study also reported there to be no difference between groups in terms of estimated volume of <b>blood loss</b> (mL) (MD ‐53.00, 95% CI ‐233.33 to 127.33 (data not in our analyses). </p> </section> </section> <section id="CD009770-sec-0126"> <h4 class="title">Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent </h4> <p>The <a href="./references#CD009770-bbs2-0005" title="PachecoLD , RosenM , GeiA , ZachariasN , PicansJ , VidalA , et al. Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Obstetrics and Gynecology2003;189(6 Suppl 1):S210. PachecoLD , RosenMP , GeiAF , SaadeGR , HankinsGD . Management of uterine hyperstimulation with concomitant use of oxytocin and terbutaline. American Journal of Perinatology2006;23(6):377‐80. ">Pacheco 2006</a> study, involving 28 women, compared two protocols for the management of uterine hyperstimulation in women receiving an oxytocin infusion: subcutaneous terbutaline (a selective ß<sub>2</sub>‐adrenergic agonist) with continuation of the oxytocin infusion versus cessation of the oxytocin infusion without a tocolytic agent. Women who were in active labour at term were included if they were receiving an oxytocin infusion for augmentation of labour and developed uterine hyperstimulation which did not resolve spontaneously within 20 minutes. Women were randomised to either receive 250 µg of subcutaneous terbutaline (up to 3 doses 15 minutes apart if hyperstimulation did not resolve) whilst the oxytocin infusion was continued, or to have the oxytocin infusion ceased without receiving any tocolytics. If uterine hyperstimulation persisted after three doses of terbutaline in the treatment group, then the oxytocin infusion was ceased. Participants with a non‐reassuring FHR tracing (i.e. fetal distress) were excluded from this study. </p> <section id="CD009770-sec-0127"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0128"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>There were no data available to analyse perinatal death or severe morbidity.</p> </section> <section id="CD009770-sec-0129"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no data available to analyse fetal or neonatal mortality.</p> </section> <section id="CD009770-sec-0130"> <h6 class="title">Caesarean delivery</h6> <p>There may be little or no difference between the subcutaneous terbutaline group (8/15) and the control (4/13) in terms of the rate of caesarean delivery (RR 1.73, 95% CI 0.68 to 4.45; low‐quality evidence; <a href="./references#CD009770-fig-0029" title="">Analysis 6.1</a>). </p> </section> </section> <section id="CD009770-sec-0131"> <h5 class="title">Secondary outcomes</h5> <p>There were no babies with <b>five‐minute Apgar scores less than seven</b> (<a href="./references#CD009770-fig-0030" title="">Analysis 6.2</a>), or <b>umbilical artery pH less than 7.0</b> (<a href="./references#CD009770-fig-0031" title="">Analysis 6.3</a>), making the relative effect inestimable. The GRADE quality of evidence was very low for both outcomes. There were no data available regarding <b>abnormal FHR</b>. The time taken for uterine hyperstimulation to resolve following treatment appeared to be shorter in the terbutaline group compared to the group for whom oxytocin was ceased (MD ‐25.19 minutes, 95% CI ‐39.96 to ‐10.42; <a href="./references#CD009770-fig-0032" title="">Analysis 6.4</a>), whilst there was no difference detected in the rate of recurrence of uterine hyperstimulation after the initial episode had resolved (RR 0.52, 95% CI 0.15 to 1.77; <a href="./references#CD009770-fig-0033" title="">Analysis 6.5</a>) (both non‐prespecified outcomes). </p> </section> </section> <section id="CD009770-sec-0132"> <h4 class="title">Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</h4> <p>The <a href="./references#CD009770-bbs2-0006" title="PatriarcoMS , ViechnickiBM , HutchinsonTA , KlaskoSK , YehSY . A study on intrauterine fetal resuscitation with terbutaline. American Journal of Obstetrics and Gynecology1987;157:384‐7. ">Patriarco 1987</a> study, involving 20 women, compared subcutaneous terbutaline, a selective ß<sub>2</sub>‐adrenergic agonist, to no tocolytic agent in women awaiting emergency delivery for the management of fetal distress. The study included women who were in labour with signs of fetal distress that had not responded to conservative management, and who had a fetal scalp blood sample with a pH less than 7.25. Eligible participants were randomised to receive either 250 µg of subcutaneous terbutaline or no tocolytic medication whilst preparations were being made for urgent caesarean section. </p> <section id="CD009770-sec-0133"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0134"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>The study authors stated that there were no differences in neonatal morbidity between the two groups, however morbidity was not defined and there was no mention of how many, if any, fetuses or neonates were defined as having morbidity. </p> </section> <section id="CD009770-sec-0135"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no perinatal deaths in either group (<a href="./references#CD009770-fig-0034" title="">Analysis 7.1</a>). The relative effect was therefore not estimable, and the quality of evidence was low. </p> </section> <section id="CD009770-sec-0136"> <h6 class="title">Caesarean delivery</h6> <p>All women in this study were delivered by caesarean section; participants were only randomised once the decision had been made for delivery by caesarean section. </p> </section> </section> <section id="CD009770-sec-0137"> <h5 class="title">Secondary outcomes</h5> <p>There was no little or no difference detected between those who received terbutaline and those who did not in the rate of <b>five‐minute Apgar scores less than seven</b> (RR 0.17, 95% CI 0.01 to 3.08; low‐quality evidence; <a href="./references#CD009770-fig-0035" title="">Analysis 7.2</a>), however the certainty in this result was low with two events in the control group compared to none in the intervention group. The mean <b>umbilical artery pH</b> was probably slightly higher in the group that received terbutaline (MD 0.08 pH, 95% CI 0.06 to 0.10; moderate‐quality evidence; <a href="./references#CD009770-fig-0036" title="">Analysis 7.3</a>). </p> <p>Those who received terbutaline were probably less likely to have an <b>abnormal FHR</b> following treatment (6/11) than the 'no tocolytic' control group (9/9) (RR 0.57, 95% CI 0.33 to 0.98; moderate‐quality evidence; <a href="./references#CD009770-fig-0037" title="">Analysis 7.4</a>), or to be classified as having <b>no improvement in FHR</b> (non‐prespecified outcome) (RR 0.13, 95% CI 0.03 to 0.59; <a href="./references#CD009770-fig-0038" title="">Analysis 7.5</a>). </p> <p>No <b>maternal side effects</b> were reported in the treatment group, however the rate was not reported for the control group. Therefore, we cannot draw any conclusions regarding this outcome. </p> </section> </section> <section id="CD009770-sec-0138"> <h4 class="title">IV terbutaline versus IV nitroglycerin</h4> <p>The <a href="./references#CD009770-bbs2-0007" title="NCT00185887 . Nitroglycerin versus terbutaline for intrapartum fetal resuscitation. clinicaltrials.gov/ct2/show/NCT00185887 (first received 16 September 2005). PullenK , TaylorL , WallerS , LangenE , DruzinM , RileyE , et al. Terbutaline versus nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S30. PullenKM , RileyET , WallerSA , TaylorL , CaugheyAB , DruzinML , et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. American Journal of Obstetrics and Gynecology2007;197(4):414.e1‐6. ">Pullen 2007</a> study, involving 110 women, compared IV terbutaline, a selective ß<sub>2</sub>‐adrenergic agonist, to IV nitroglycerin (a nitric oxide donor) for the management of fetal distress. Women who were in labour or who were admitted for induction of labour, and who were between 32 and 42 weeks' gestational age, were included if they had a non‐reassuring FHR tracing that did not respond to conservative management. Eligible women were randomised to receive either 250 µg of IV terbutaline or 400 µg of IV nitroglycerin. </p> <section id="CD009770-sec-0139"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0140"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>There were no data available to analyse perinatal death or severe morbidity.</p> </section> <section id="CD009770-sec-0141"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no data available to analyse fetal or neonatal mortality.</p> </section> <section id="CD009770-sec-0142"> <h6 class="title">Caesarean delivery</h6> <p>There may be little or no difference between the terbutaline group (30/57) and the nitroglycerin group (29/53) in the rate of caesarean section (RR 0.96, 95% CI 0.68 to 1.36; low‐quality evidence; <a href="./references#CD009770-fig-0039" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD009770-sec-0143"> <h5 class="title">Secondary outcomes</h5> <p>No women in either group had <b>five‐minute Apgar scores less than seven</b> (<a href="./references#CD009770-fig-0040" title="">Analysis 8.2</a>), making the relative effect inestimable (low‐quality evidence.) We are uncertain of the effects on <b>umbilical artery pH less than 7.0</b> (RR 4.87, 95% CI 0.24 to 98.18; very low‐quality evidence; <a href="./references#CD009770-fig-0041" title="">Analysis 8.3</a>), however numbers were low with two events in the terbutaline group and none in the nitroglycerin group. There appeared to be no clear difference in the rate of <b>successful intrauterine fetal resuscitation</b> (non‐prespecified outcome) (RR 1.12, 95% CI 0.87 to 1.45; <a href="./references#CD009770-fig-0044" title="">Analysis 8.6</a>). </p> <p>Those in the terbutaline group (1/57) were less likely to have <b>uterine tachysystole</b> 10 minutes after drug administration compared to the nitroglycerin group (10/53) (RR 0.09, 95% CI 0.01 to 0.70; <a href="./references#CD009770-fig-0042" title="">Analysis 8.4</a>), however there was no clear difference in the need for a <b>repeat dose of tocolytic agent</b> (RR 1.24, 95% CI 0.57 to 2.70; <a href="./references#CD009770-fig-0043" title="">Analysis 8.5</a>). There was also no difference detected between the terbutaline and the nitroglycerin group in terms of the presence of <b>meconium‐stained amniotic fluid</b> (RR 0.93, 95% CI 0.51 to 1.71; <a href="./references#CD009770-fig-0045" title="">Analysis 8.7</a>), <b>admission to the NICU</b> (RR 0.93, 95% CI 0.46 to 1.89; <a href="./references#CD009770-fig-0046" title="">Analysis 8.8</a>), or <b>postpartum haemorrhage</b> (RR 1.39, 95% CI 0.24 to 8.02; <a href="./references#CD009770-fig-0047" title="">Analysis 8.9</a>). </p> </section> </section> <section id="CD009770-sec-0144"> <h4 class="title">IV salbutamol versus sublingual nifedipine</h4> <p>The <a href="./references#CD009770-bbs2-0008" title="RudraT , ThirumalS , NaguleswaranK , RudraS . Impact of nifidipine for acute tocolysis in acute fetal distress. 31st British International Congress of Obstetrics and Gynaecology; 2007 July 4‐6; London, UK. 2007:58. ">Rudra 2007</a> study, involving 75 women, compared IV salbutamol, a selective ß<sub>2</sub>‐adrenergic agonist, to sublingual nifedipine, a calcium channel blocker, for the management of fetal distress. This study was presented in abstract form with limited description of the methods used. Women with severe cardiotocographic abnormalities were included once the decision had been made to perform an urgent caesarean section. The dosage and administration protocol of the two treatments was not described. </p> <section id="CD009770-sec-0145"> <h5 class="title">Primary outcomes</h5> <section id="CD009770-sec-0146"> <h6 class="title">Perinatal death or severe morbidity</h6> <p>There were no data available to analyse perinatal death or severe morbidity.</p> </section> <section id="CD009770-sec-0147"> <h6 class="title">Fetal or neonatal mortality</h6> <p>There were no data available to analyse fetal or neonatal mortality.</p> </section> <section id="CD009770-sec-0148"> <h6 class="title">Caesarean delivery</h6> <p>There were no data available to analyse caesarean section rates. Women were only included once the decision had already been made to deliver by urgent caesarean section. </p> </section> </section> <section id="CD009770-sec-0149"> <h5 class="title">Secondary outcomes</h5> <p>There were no data that were presented in a form that was able to be entered into the data analysis for this review. The study authors did note that women treated with salbutamol had a higher rate of maternal side effects, uterine hypotonia and peripartum blood loss than those treated with nifedipine. Whilst they report that there was no significant influence on perinatal outcomes, infants in the nifedipine group were significantly more likely to require ventilatory support after delivery (30.5% versus 7.7%). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009770-sec-0150" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009770-sec-0150"></div> <section id="CD009770-sec-0151"> <h3 class="title" id="CD009770-sec-0151">Summary of main results</h3> <p>This review included eight studies (involving 734 women), however, all but one of our comparisons were based on data from single studies with small numbers of participants. All of the included studies used a selective ß<sub>2</sub>‐agonist in one of their study arms, however, the specific drug varied from study to study, as did the comparison. Overall, the use of a tocolytic agent appeared to improve some measures of fetal well‐being and reduce uterine tachysystole, though no studies demonstrated any improvement in neonatal condition, or in the primary outcomes for the review. However, the limited data for most outcomes means specific conclusions cannot be drawn. </p> <p>Regarding specific comparisons:</p> <p> <ol id="CD009770-list-0017"> <li> <p>Women who received a selective ß<sub>2</sub>‐adrenergic agonist whilst awaiting emergency delivery for fetal distress were more likely to experience an improvement in the fetal heart rate (FHR) tracing than those who received no treatment. There was no difference detected between the groups in the rate of Apgar scores less than seven at five minutes, and the intervention may make little or no difference to this outcome. </p> </li> <li> <p>Atosiban for the treatment of fetal distress was associated with fewer cases of maternal palpitations or tachycardia than hexoprenaline, with no differences detected between the two across other outcomes. The small sample size means that rare events, such as fetal or neonatal mortality or severe morbidity, were unlikely to be detected. </p> </li> <li> <p>Women who received fenoterol for fetal distress were less likely to have infants that required admission to a neonatal intensive care unit (NICU) than women who were delivered by emergency delivery, however they were more likely to deliver by caesarean section. This was hypothesised to be due to reduced uterine contractility in the fenoterol group, reducing the likelihood of a vaginal delivery. We did not detect any differences across any other outcomes. </p> </li> <li> <p>Women who received hexoprenaline whilst awaiting emergency delivery for fetal distress, compared to those who did not, were less likely to have meconium‐stained liquor and were more likely to show an improvement in the FHR tracing. We did not detect any differences between groups in other outcomes, including mortality and morbidity, Apgar scores, umbilical artery pH or NICU admission. </p> </li> <li> <p>Women who received terbutaline whilst awaiting emergency delivery, compared to those who did not, were more likely to show an improvement in the FHR tracing. We did not detect any differences in any other outcomes including Apgar score, umbilical artery pH or maternal side effects. </p> </li> <li> <p>We did not detect any differences in the umbilical artery pH, resolution of fetal distress or maternal blood loss between women treated with terbutaline for fetal distress and those treated with magnesium sulphate. </p> </li> <li> <p>Women treated with terbutaline for fetal distress were less likely to have uterine tachysystole following treatment than those treated with nitroglycerin, however we did not detect any differences between groups in caesarean section rates, successful intrauterine fetal resuscitation or measures of neonatal well‐being postpartum. </p> </li> <li> <p>In women receiving oxytocin for labour augmentation who developed uterine hyperstimulation, hyperstimulation resolved faster in women who received terbutaline and continued the oxytocin compared to those who had the oxytocin infusion ceased. We did not detect any differences between the groups in terms of caesarean section rates, Apgar scores or umbilical artery pH. The rate of recurrence of uterine hyperstimulation was also not different between groups. </p> </li> </ol> </p> </section> <section id="CD009770-sec-0152"> <h3 class="title" id="CD009770-sec-0152">Overall completeness and applicability of evidence</h3> <p>We were unable to pool findings for most interventions due to the heterogeneity in intervention and comparison groups and reported outcomes. Many of the outcomes that are of key clinical significance in this context, such as maternal morbidity and fetal and neonatal mortality and morbidity, are rare events (particularly in higher‐income countries), and the small sample sizes mean that the sensitivity of the included studies for detecting these events was very low. </p> <p>It was difficult to directly compare studies due to the variety of interventions and outcome definitions used, meaning only one meta‐analysis was possible. In the only two studies that we could meta‐analyse, the study protocols and drug used (ß<sub>2</sub>‐adrenergic agonist) differed, hence the clinical applicability of the findings are unclear. </p> <p>The majority of studies are from high‐income countries in facilities with access to caesarean section, which may limit the generalisability of the results to lower‐resource settings, or settings where caesarean section is not available. </p> </section> <section id="CD009770-sec-0153"> <h3 class="title" id="CD009770-sec-0153">Quality of the evidence</h3> <p>The methodological qualities of the studies included was variable. One was published only in abstract form and did not include enough information to assess any aspects of bias. Most studies used adequate randomisation and allocation concealment. No studies were placebo‐controlled, and blinding was inadequate or impossible in all but one study due to the significant differences between interventions in terms of approach to management or route of drug administration. Overall, the included studies had a low risk of bias for random sequence generation, allocation concealment, incomplete data and selective reporting, and a high risk of bias in blinding methods. </p> <p>There was generally not a clearly defined management pathway for women in control groups, in terms of medications they could and could not receive in the trial ‐ this could introduce potential confounders that were not assessed. There was limited blinding of outcome assessment, with only two studies adequately blinding assessors. We judged most studies to have a low risk of both reporting and attrition bias. </p> <p>We assessed the quality of the evidence using the GRADE system, and generally found it to be of low‐ to moderate‐quality. We downgraded all studies by one or two levels for imprecision, and also some due to risk of bias. </p> </section> <section id="CD009770-sec-0154"> <h3 class="title" id="CD009770-sec-0154">Potential biases in the review process</h3> <p>There is potential for bias in each step of the review process, however we attempted to limit this. Our search strategy was supported by Cochrane Pregnancy and Childbirth, and at least two review authors evaluated each identified study for inclusion, data extraction and quality assessment. In cases of disagreement, results were discussed and a third review author was consulted. One review author (JH) was a co‐author of an included study (<a href="./references#CD009770-bbs2-0003" title="KulierR , GulmezogluAM , HofmeyrGJ . Betamimetics for fetal distress: a randomized trial. 14th Conference on Priorities in Perinatal Care in South Africa; 1995 March 7‐10; South Africa. 1995:190‐3. KulierR , GulmezogluAM , HofmeyrGJ , VanGelderenCJ . Betamimetics in fetal distress: a randomised controlled trial. Journal of Perinatal Medicine1997;25(1):97‐100. ">Kulier 1997</a>), and was not involved in any decisions or assessments pertaining to this study. Despite our efforts, any assessment of studies is subjective in nature; a different team of review authors may have made a different assessment of the evidence. </p> </section> <section id="CD009770-sec-0155"> <h3 class="title" id="CD009770-sec-0155">Agreements and disagreements with other studies or reviews</h3> <p>The previous Cochrane Review on tocolytics for suspected intrapartum fetal distress (<a href="./references#CD009770-bbs2-0059" title="KulierR , HofmeyrGJ . Tocolytics for suspected intrapartum fetal distress. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000035] ">Kulier 2000</a>), found that betamimetics reduced FHR abnormalities and uterine activity, however, it found insufficient evidence to comment on clinically important outcomes or evaluate the role of betamimetics for suspected fetal distress. Our review includes six additional studies compared to the earlier review, however the main conclusions remain unchanged. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009770-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009770-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009770-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009770-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 1 Fetal or neonatal mortality." data-id="CD009770-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 1 Fetal or neonatal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 3 Fetal heart rate tracing not improved." data-id="CD009770-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 3 Fetal heart rate tracing not improved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 1 Perinatal death or severe morbidity." data-id="CD009770-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 1 Perinatal death or severe morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 2 Fetal or neonatal mortality." data-id="CD009770-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 2 Fetal or neonatal mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 3 Caesarean delivery." data-id="CD009770-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 3 Caesarean delivery.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 4 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 4 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 5 Umbilical artery pH." data-id="CD009770-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 5 Umbilical artery pH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 6 Abnormal fetal heart rate tracing." data-id="CD009770-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 6 Abnormal fetal heart rate tracing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 7 Maternal side effects (tachycardia or palpitations)." data-id="CD009770-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 7 Maternal side effects (tachycardia or palpitations). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 8 Admission to NICU." data-id="CD009770-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 8 Admission to NICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 1 Caesarean delivery." data-id="CD009770-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 1 Caesarean delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 3 Umbilical artery pH &lt; 7.1." data-id="CD009770-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 3 Umbilical artery pH &lt; 7.1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 4 Umbilical cord blood base excess &lt; ‐12." data-id="CD009770-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 4 Umbilical cord blood base excess &lt; ‐12. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU." data-id="CD009770-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 1 Fetal or neonatal mortality." data-id="CD009770-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 1 Fetal or neonatal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 3 Umbilical artery pH &lt; 7.2." data-id="CD009770-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 3 Umbilical artery pH &lt; 7.2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 4 Fetal heart rate tracing not improved." data-id="CD009770-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 4 Fetal heart rate tracing not improved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 5 Meconium‐stained amniotic fluid." data-id="CD009770-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 5 Meconium‐stained amniotic fluid. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 6 Umbilical cord blood base excess &lt; ‐10." data-id="CD009770-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 6 Umbilical cord blood base excess &lt; ‐10. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 7 Admission to NICU." data-id="CD009770-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 7 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH &lt; 7.2." data-id="CD009770-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH &lt; 7.2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal distress on fetal heart rate tracing." data-id="CD009770-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal distress on fetal heart rate tracing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 1 Caesarean delivery." data-id="CD009770-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 1 Caesarean delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 2 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 2 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 3 Umbilical artery pH &lt; 7.0." data-id="CD009770-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 3 Umbilical artery pH &lt; 7.0. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 4 Time to resolution of uterine hyperstimulation." data-id="CD009770-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 4 Time to resolution of uterine hyperstimulation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 5 Recurrence of hyperstimulation after initial resolution." data-id="CD009770-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic, Outcome 5 Recurrence of hyperstimulation after initial resolution. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 1 Fetal or neonatal mortality." data-id="CD009770-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 1 Fetal or neonatal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 2 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 3 Umbilical artery pH." data-id="CD009770-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 3 Umbilical artery pH. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 4 Abnormal FHR." data-id="CD009770-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 4 Abnormal FHR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 5 No improvement in FHR." data-id="CD009770-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome 5 No improvement in FHR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery." data-id="CD009770-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score &lt; 7." data-id="CD009770-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH &lt; 7.0." data-id="CD009770-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH &lt; 7.0. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes after drug." data-id="CD009770-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes after drug. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose of tocolytic." data-id="CD009770-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose of tocolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation." data-id="CD009770-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid." data-id="CD009770-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU." data-id="CD009770-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009770-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/urn:x-wiley:14651858:media:CD009770:CD009770-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_t/tCD009770-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage." data-id="CD009770-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/media/CDSR/CD009770/image_n/nCD009770-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Selective ß<sub>2</sub>‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with fetal distress for whom the decision had been made to delivery by emergency caesarean section<br/> <b>Setting:</b> hospitals with the capacity for caesarean section in South Africa or the United States<br/> <b>Intervention:</b> ß<sub>2</sub>‐adrenergic receptor agonist whilst awaiting emergency delivery<br/> <b>Comparison:</b> no tocolytic whilst awaiting emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no tocolytic agent whilst awaiting emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ß<sub>2</sub>‐ adrenergic receptor agonist whilst awaiting emergency delivery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/> (0.01 to 4.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>57<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (1 to 314) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery was an inclusion criteria for both trials</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/> (0.02 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (3 to 224) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low umbilical artery pH (less than 7.0 or as defined by trial authors)</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abnormal FHR as defined by trial authors (FHR tracing not improved)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.28<br/> (0.08 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>947 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/> (133 to 521) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Wide confidence interval crossing the line of no effect (‐1).<br/> <sup>2</sup>Small sample size (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for IV atosiban versus IV hexoprenaline</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV atosiban versus IV hexoprenaline for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with severe intrapartum fetal bradycardia<br/> <b>Setting:</b> Austrian hospital with capacity for caesarean section<br/> <b>Intervention:</b> IV atosiban (6.75 mg)<br/> <b>Comparison:</b> IV hexoprenaline (5 µg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV hexoprenaline</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV atosiban</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 7.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 577) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>26</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 (0 to 0)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 7.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical artery pH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean umbilical artery pH was 7.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in umbilical artery pH in the intervention group was 0 (0.05 fewer to 0.05 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Abnormal FHR tracing</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 3.00<br/> (0.13 to 67.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>26<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Small sample size (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect (‐1).<br/> <sup>3</sup>Few/no events (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for IV atosiban versus IV hexoprenaline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for IV fenoterol bromhydrate versus emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV fenoterol versus emergency delivery for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole<br/> <b>Setting:</b> hospital in Uruguay with capacity for caesarean section<br/> <b>Intervention:</b> IV fenoterol bromhydrate (0.1 mg/minute, titrated according to response)<br/> <b>Comparison:</b> emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV fenoterol bromhydrate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (1.04 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>807 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>904 per 1000<br/> (839 to 985) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/> (0.35 to 4.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (7 to 95) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/> (0.44 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/> (94 to 224) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal FHR tracing</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Participants, clinicians and assessors were not blinded. There were risks identified for reporting bias (‐1).<br/> <sup>2</sup>Confidence interval crossing the line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for IV fenoterol bromhydrate versus emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings for IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring<br/> <b>Setting:</b> hospital in South Africa with capacity for caesarean section<br/> <b>Intervention:</b> IV hexoprenaline (10 µg) whilst awaiting emergency delivery<br/> <b>Comparison:</b> no tocolytic whilst awaiting emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no tocolytic whilst awaiting emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV hexoprenaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/> (0.01 to 4.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (1 to 455) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/> (0.01 to 4.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 481) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/> (0.30 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>588 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>376 per 1000<br/> (176 to 794) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>FHR tracing not improved</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.43<br/> (0.21 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000<br/> (189 to 792) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Small sample size (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings for IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline versus IV magnesium sulphate</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subcutaneous terbutaline versus IV magnesium sulphate for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with intrapartum fetal distress for whom the decision had been made to deliver by caesarean section<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> subcutaneous terbutaline (250 µg) followed by caesarean section within 15 minutes<br/> <b>Comparison:</b> IV magnesium sulphate (4 g) followed by caesarean section within 15 minutes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV magnesium sulphate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous terbutaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.2</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.29<br/> (0.07 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>46<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>304 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (21 to 374) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resolution of fetal distress on FHR tracing</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.31<br/> (0.97 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>46<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>696 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>911 per 1000<br/> (675 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Participants, clinicians and assessors unblinded (‐1).<br/> <sup>2</sup>Small sample size (‐1).<br/> <sup>3</sup>Confidence interval crossing the line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline versus IV magnesium sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent for the management of uterine hyperstimulation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women who developed uterine hyperstimulation in labour with oxytocin augmentation, but without signs of fetal distress<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> subcutaneous terbutaline (250 µg, up to 3 doses 15 minutes apart) with continuation of the oxytocin infusion<br/> <b>Comparison:</b> cessation of the oxytocin infusion without administration of a tocolytic </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with cessation of oxytocic infusion without tocolytic</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous terbutaline with continuation of oxytocic</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.73<br/> (0.68 to 4.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532 per 1000<br/> (209 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal FHR tracing</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No blinding of participants, clinicians or assessors (‐1).<br/> <sup>2</sup>Confidence interval crossing the line of no effect (‐1).<br/> <sup>3</sup>No events in either group (‐1).<br/> <sup>4</sup>Small sample size (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in labour with signs of fetal distress and a fetal scalp pH &lt; 7.25, for whom the decision had been made for emergency delivery<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> subcutaneous terbutaline (250 µg) whilst awaiting emergency delivery<br/> <b>Comparison:</b> no tocolytic whilst awaiting emergency delivery </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no tocolytic whilst awaiting emergency delivery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous terbutaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean delivery</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.17<br/> (0.01 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (2 to 684) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical artery pH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean umbilical artery pH in the intervention group was 0.08 more (0.06 more to 0.1 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abnormal FHR tracing</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.33 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>570 per 1000<br/> (330 to 980) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No improvement in FHR</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.13<br/> (0.03 to 0.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000<br/> (30 to 590) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FHR</b> : fetal heart rate; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval crossing the line of no effect (‐1).<br/> <sup>2</sup>Small sample size (‐1).<br/> <sup>3</sup>No events in either group (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings for subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009770-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings for IV terbutaline versus IV nitroglycerin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IV terbutaline versus IV nitroglycerin for the management of intrapartum fetal distress</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with non‐reassuring FHR tracing during labour or induction of labour<br/> <b>Setting:</b> hospital in the USA with capacity for caesarean section<br/> <b>Intervention:</b> IV terbutaline (250 µg)<br/> <b>Comparison:</b> IV nitroglycerin (400 µg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV nitroglycerin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV terbutaline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal death or severe morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal or neonatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.68 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>547 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000<br/> (372 to 744) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5‐minute Apgar score &lt; 7</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Umbilical artery pH &lt; 7.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.87<br/> (0.24 to 98.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Successful intrauterine fetal resuscitation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12</p> <p>(0.87 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐prespecified. See <a href="#CD009770-sec-0170">Differences between protocol and review</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>718 per 1000</p> <p>(559 to 932)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval crossing the line of no effect (‐1).<br/> <sup>2</sup>No events in either group (‐1).<br/> <sup>3</sup>Small sample size (‐1).<br/> <sup>4</sup>Extremely wide confidence interval (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Summary of findings for IV terbutaline versus IV nitroglycerin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/full#CD009770-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fetal or neonatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fetal heart rate tracing not improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IV atosiban versus IV hexoprenaline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death or severe morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fetal or neonatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Caesarean delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Umbilical artery pH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.05, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Abnormal fetal heart rate tracing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maternal side effects (tachycardia or palpitations) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.1 [0.01, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IV atosiban versus IV hexoprenaline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">IV fenoterol bromhydrate versus emergency delivery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Caesarean delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.04, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.35, 4.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Umbilical artery pH &lt; 7.1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Umbilical cord blood base excess &lt; ‐12 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.46, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">IV fenoterol bromhydrate versus emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fetal or neonatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Umbilical artery pH &lt; 7.2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.30, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fetal heart rate tracing not improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.21, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Meconium‐stained amniotic fluid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.09, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Umbilical cord blood base excess &lt; ‐10 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.13, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.15, 80.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subcutaneous terbutaline versus IV magnesium sulphate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Umbilical artery pH &lt; 7.2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.07, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Resolution of fetal distress on fetal heart rate tracing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.97, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subcutaneous terbutaline versus IV magnesium sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Caesarean delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.68, 4.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Umbilical artery pH &lt; 7.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Time to resolution of uterine hyperstimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.19 [‐39.96, ‐10.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrence of hyperstimulation after initial resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.15, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fetal or neonatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 3.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Umbilical artery pH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.06, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Abnormal FHR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.33, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 No improvement in FHR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.03, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009770-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">IV terbutaline versus IV nitroglycerin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Caesarean delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.68, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Five‐minute Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Umbilical artery pH &lt; 7.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [0.24, 98.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Uterine tachysystole 10 minutes after drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for repeat dose of tocolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.57, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Successful fetal intrauterine resuscitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.87, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Meconium‐stained amniotic fluid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.51, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.46, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.24, 8.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">IV terbutaline versus IV nitroglycerin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009770.pub2/references#CD009770-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009770.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009770-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009770-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009770-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009770-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009770-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009770-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009770\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009770\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009770\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009770\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009770.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009770.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009770.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009770.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009770.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720316130"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009770.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720316133"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009770.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfe31eef09377',t:'MTc0MDcyMDMxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 